Gertz, D. see Delaney, J. F.
Giammana, S. T. see Handmaker, H.
Gilday, D. L., Hitch, D., Shandling, B. and Ash, J. Imaging for tectricular torsion in pediatric surgery, 553*

Gilday, D. L.
see Alderson, P. O.
see Ash, J.
see Brown, R. G.
see Hitzal, E. P.
see Kilburn, E.

Gill, S. P.
see Beierwaltes, W. H.
see Sarkar, S. D.

Gilson, A. J.
see Kenny, P. J.
see Watson, D. D.

Girscheck, P. K. see Saha, G. B.

Glass, H. I. see Hudson, F. R.

Gleghorn, B.
see Verma, R. C.
see Webber, M. M.

Glehn, H. J. see Konikowski, T.

Gloria, I. V. see Lopop, K. A.

Go, R. T. see Christie, J. H.

Goergen, T. G., Resnick, D., Lomonaco, A. and O’Dell, C. W. Bone scan abnormalities in leprosy, 788

Gold, E. N. see Sarkar, S. D.

Goldberg, M. E. see Frick, M. P.

Goldfarb, S. see Kis, C. M.

Goldsmith, S. J. and Kagan, A. Effect of thyroid hormone on plasma immunoreactive insulin, 533*

Goldsmith, S. J. see Guter, M.

Gollnick, D. A. see Mpanias, P.

Goodrich, J. K.
see How, W. R.
see Jones, R. H.

Goodwin, D. A., Meares, C. F., Leung, C. S. H., Silvester, D. J., Nunn, A. D. and Lavender, P. J. "In-EDTA-HSA preparation and distribution, 561*

Gooneratne, N. and Conway, J. J. Radionuclide angiographic diagnosis of bronchopulmonary sequestration, 1035

Gorin, A. B., Weidner, J. and Staub, N. Pulmonary vascular permeability measurement, 541*

Goris, M. L. The difference between t and t_\text{nu}, 759

Goris, M. L., Daspit, S. G., McLaughlin, P. and Kriss, J. P. Interpolative background subtraction, 744

Goris, M. L., Lamb, J. F., Daspit, S. G. and McRae, J. "Kr estimation of regional lung ventilation, 530*

Goris, M. L. see Daspit, S. G.
see Gates, G. F.

Gorman, C. A. see Robertson, J. S.
Gottoff, S. P. see Papiernik, C. K.

Gottlieb, S. see Groch, M. W.

Gottschalk, A.
see Caride, V. J.
see Marshall, R. C.

Gould, K. L. see Hamilton, G. W.

Goy, W. and Crowe, W. J. Spleen uptake of \(^{99m}\)Tc-diphosphonate in sickle cell disease, 108

Graham, K. D.
see Parker, W. R.
see Stokely, E. M.

Graham, L. S., Poe, N. D. and Mac Donald, N. S. Collimation for imaging the myocardium, 401

Graham, L. S., Poe, N. D. and Robinson, G. D. Collimation for imaging the myocardium, 719

Grant, R. W. and Ackery, D. Spleen displacement in infected pancreatic pseudocyst, 193

Green, J. P., Wilcox, J. R., Marriot, J. D., Halpern, S. E. and Crews, Q. E. Comparison of capsules and liquid for thyroid uptake of \(^{131}\)I, 310

Green, M. V., Brody, W. R., Douglas, M. A., Redwood, D. R., Bayles, J. J. and Johnson, G. S. Count rate measurement of left ventricular ejection fraction from gated images, 557*

Green, M. V. see Bacharach, S. L.

Green, N., Swanson, L., Kern, W., Homann, R., Irwin, L. and Berne, C. J. Lung images in lymphangitic carcinomatosis, 258

Greenberg, M. see Hutsal, E. P.

Greenfield, M. A. see Mpanias, P.

Grenier, R. P. Performance of scintillation cameras, 665

Greyson, N. D. and Kassel, E. E. Serial scan changes in recurrent bone infarction, 184

Groch, M. W., Gottlieb, S., Mallon, S. M. and Miale, A. A portable dual probe system for left ventricular function, 930

Groch, M. W. and Lewis, G. K. Considerations for imaging with \(^{201}\)TI, 142

Grossman, Z. D., Brian, P., Dinn, M., McAfee, J. G., Wistow, B. and Bassano, D. Comparison of imaging, ultrasonography, and axial tomography of the liver, 544*

Grossman, Z. D., Foster, A. B., Richardson, R., McAfee, J. G., Subramanian, G., Markarian, B., Bassano, D. and Gagne, G. Uptake of \(^{99m}\)Tc agents and \(^{99m}\)Sr in myocardial infarct, 534*

Grossman, Z. D. see McAfee, J. G.

Groove, R. B. see Opetch, J. A.

Guiberteau, J. M., Rosaids, M. S. and McKusiel, K. A. "\(^{99m}\)Tc-diphosphonate uptake by hepatic neoplasms, 1060

Gullberg, G. T. see Budinguer, T. F.

Gumerman, L. W. see Levine, G.

Gunther, C. W., Wilkerson, S. V. and Floridiana, D. G. Assay of \(^{99m}\)Tc, 1109


Gutkowski, R. F., Dworkin, H. J., Porter, W. C. and Rohwer, T. Preparation of \(^{99m}\)Tc-red blood cells, 942

Gutkowski, R. F., Dworkin, H. J., Porter, W. C. and Rohwer, H. Radiolabeling of red blood cells, 1113

Gutkowski, R. F. see Porter, W. C.

Hagan, P. L. see Chauncey, D. M.

Hall, E. J. see George, E. A.

Haines, J. E. see Yeung, W. C.

Hale, T. I. "\(^{99m}\)Tc labeling of streptokinase, 226

Hall, F. M. see Diffey, B. L.


Hall, A. C. see Campeau, R. F.

Hall, P. see Taylor, A. T.

Hall, R. see Wistow, B.

Halpern, S. E. see Chauncey, D. M.
see Green, J. P.
see Preisman, R.
see Taylor, A.

Hamamoto, K. see Morita, R.

Hambricht, P., McRae, J. and Bearden, A. Chemical state of Tc in vivo, 424

hambricht, P., McRae, J., Valk, P., Bearden, A. J. and Shipley, B. Chemical state of Tc in vivo, 422

Hambright, P. see McRae, J.

Hamburger, J. I. see Stoffer, S. S.

Hamilton, G. W., Trobaugh, G. B., Ritchie, J. L. and Weaver, W. D. Rest and exercise \(^{201}\)TI myocardial imaging, 522*

Hamilton, G. W., Weaver, W. D., Williams, D. L., Ritchie, J. L., Caldwell, J. and Kennedy, J. W. Ejection fraction from first-transit data, 556*

Hamilton, G. W., Williams, D. L. and Gould, K. L. Selection of appropriate frame rates for radiouclide angiography, 556*

Hamilton, G. W. see Weaver, W. D.

Hamilton, R. G., Alderson, P. O., Harwig, J. F. and Siegel, B. A. Spleen imaging with \(^{99m}\)Tc-red blood cells, 561*

Hamilton, R. G., Alderson, P. O., Harwig, J. F. and Siegel, B. A. \(^{99m}\)Tc-RBC spleen imaging, 1038

Hammersley, P. A. G. and Zivomovic, M. A. \(^{99m}\)Tc uptake in regenerating rat liver, 226

Handmaker, H. and Giammana, S. T. Combined \(^{99m}\)Tc-phosphate and \(^{99m}\)Ga-citrate for joint imaging, 554*

Handmaker, H. see Hoffer, P. B.

Hannah, T. see Brown, M. L.

Harbert, J. C. Focal renal activity in bone scans, 426

Hart, J. C. see Alleva, J. J. and Sandoek, K. L. Gallbladder visualization in adenal scarring, 33
cal venous reflux in dynamic brain imaging, 9
Hayt, D. B. and Perez, L. A. Jugular vein reflux, 225
Hayt, D. B. see Perez, L. A.
Hedley-White, E. T. see Treves, S.
Heerfordt, J., Vitsisen, L. and Bohr, H. "F and 51Cr-polyporphosphate bone scanning in orthopedics, 98
Heerwald, E. see Krejcarek, G. E.
Heederiks, W., J. see Keyes, J. W.
Heidenreich, P. see Hör, G.
Heise, C. M. Measurement of serum Tc, 665
Helson, L. R. see Pettit, W. A.
Hendershot, L. R. see Henry, R. E.
Henderson, R. W. see Subramanian, G.
see Wistow, B.
Henkin, R. E. Book review; Clinical Scintillation Imaging, 761
Henning, H., Schelbert, H., O'Rourke, R. A., Righetti, A., Hardarson, T. and Ashburn, W. L. Dual 99mTc-pyrophosphate and 111In imaging for acute myocardial infarct, 524*
Henry, J. E. see Taylor, A. T.
Henry, R. E., George, E. A. and Donati, R. M. Computer-generated images of regional hepatic perfusion, 532*
Henry, R. E., Somogyi, M. M., Hendershot, L. R., Klos, D. J., George, E. A. and Donati, R. M. Lung uptake of 123I-platelets, 511Fibrinogen, and 51Cr-S colloidal after endotoxin, 543*
Henry, R. E. see George, E. A.
Herbig, F. K. see Fletcher, J. W.
Herbst, K. D. and Corder, M. P. Radiotlherapy-induced liver scan defects, 424
Herdt, J. R. L. see Russell, C. D.
Hertsgaard, D. B. see Patton, D. D.
Hessel, S. J. see McNeil, B. J.
Higgins, C. S. see Hoffman, E. J.
Hinn, G. M. see Lewellen, T. K.
Hiss, J. M. see Krishnamurthy, G. T.
Hitcho, D. see Gilday, D. L.
Hnatowich, D. J. 51Ga labeling of Sn-soaked albumin microspheres, 57
Hnatowich, D. J. Preparation of 51Ga radiopharmaceuticals, 228
Hnatowich, D. J., Kulprathipanju, S. and Treves, S. Osmium-iridium generator, 555*
Hnatowich, D. J. see Dewanjee, M. K. see Hoop, B.
Ho, J. E. Book review; Pediatric Nuclear Medicine, 512
Hofeldt, F. D. see Rosenthal, S. L. see Verdon, T. A.
Hoffer, P. B. see Bekerman, C. see Lim, C. B. see Sickles, E. A. see Swann, S.
Hoffman, E. J. see Phelps, M. E.
Hollen, J. E. see Kim, C. M. see Sickles, E. A. see Swann, S.
Hollifield, J. W. see Patton, J. A.
Holman, B. L., Jones, A. G., Davis, M. A., Arakali, J. and Maroko, P. R. Double-labeling of acute myocardial infarcts, 508
Holman, B. L. see Davis, M. A.
Holmes, R. A. Book review; Basic Nuclear Medicine, 761
Holmes, R. A. Book review; Medical Malpractice Law, 669
Holmes, R. A. see Soin, J. S.
see Zimmer, A. M.
Holmquest, D. L. and Lake, P. Sudden hemorrhage in thyroid carcinoma metastatic to brain, 307
Homann, R. see Green, N.
Hoop, B. see Correia, J. A. see Yano, Y.
Hoosier, C. W. see Chafez, N.
Hör, G., Heidenreich, P., Kriegel, H. and Langhammer, H. Breast imaging with 51TcO4 and 51Ga-citrate, 223
Horgan, J. D. see Sebern, M. J.
Horiuchi, K. see Yokoyama, A.
Horn, N. L. and Bennett, L. R. Comparison of dual probe and tomographic scanning for "In-hematocrit studies, 547*
Hoshi, Y. see Toyama, H.
Hosokawa, S. see Ishii, Y.
Howe, W. R., Goodrich, J. K., Bruno, F. P., Jones, R. H., Wechsler, J. A. and Oldham, H. N. 99mTc-pyrophosphate detection of post-surgery myocardial infarct, 524*
see Jones, R. H.
Howorth, P. J. N. and Marsden, P. Rapid Tc radiomunooassay kit, 321
Howorth, P. J. N. and Marsden, P. Tc by the Ames kit, 943
Hreusch, F. W. see Billinghurst, M. W.
Huang, S. M. see DeNardo, G. L. see DeNardo, S. J. see Wortman, J.
Huard, D. see Jaszczak, R.
Ruetz, P. P. see Sebern, M. J.
Rujanaveeh, N., Mattar, A. G. and Coleman, R. E. Rapid-sequence imaging in subdural empyema, 980
Russ, G. see Bigler, R. E.
Russ, G. R. see Pettit, W. A.
Russell, C. D., Jander, H. P. and Dubovsky, E. V. False-positive results in subdural hematomas, 327
Russell, C. D., Jones, A. E., Johnston, S. G. and Herdt, J. R. L. Focal defect in colloid spleen scan, 376
Russell, R. O. see Logic, J. R.
Russin, R. D. and Staeh, E. V. Bone scan findings in acute osteomyelitis, 617
Ruzicka, S. and Samols, E. see Dubovsky, E. V.
Ryo, S. Sakamoto, B. J. and Saenger, R. see Ishii, Y.
Ryo, S. and Toki, Y. Imaging and management of subdural hematoma, 532*
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
S.
1976 SUBJECT INDEX

Asterisk indicates abstract

**Abdomen**  
see also specific organ  
abscess, *Ga-citrate scanning, ultrasound, 545*  
aortic aneurysms, angiography, 327*, 765*, 1065  
aortic aneurysms, ultrasound, 327*  
mesenteric cyst, ultrasound, 860*  
*P*-chronic phosphate therapy, distribution, **Tc-HSA, 150, 151  
tuberculosis peritonitis, *Ga-citrate scan, 272, 1020  
tuberculous peritonitis, ultrasound guided percutaneous puncture, 432*  

**Abscess**  
abdominal, *Ga-citrate scanning and ultrasound, 545*  
**Ga-citrate uptake, Fe dextran effect, in rabbits, 356  
imaging, *Ga-leukocytes, 434*  
In-leukocytes, uptake, in dogs, 560*  
liver, comparison of ultrasound, **Tc-S colloid imaging  
and axial tomography, 544*  
lung, dynamic perfusion imaging, **TcO₂, 541*  
Pb-acetate, *Ga-citrate uptake, in rats, 800  
pelvic, ultrasonography, 1028*  
perinephric, *Tc-glucoheptonate, *Ga-citrate, subtraction method, 858*  
renal, *Ga-citrate scan, 872  

**Adrenal glands**  
carcinoma, metastatic to liver, *Iodomethylnorchol- 
tenol scan, 904  
*H-, *T*-enzyme inhibitors, preparation, distribution, in  
dogs, 925*, 998  
imaging, *I*-cholesterol, 563*  
imaging, *I*-cholesterol, gallbladder uptake, 33  
imaging, *I*-cholesterol, renovascular hypertension, 378  
*I*-iodomethylnorcholesterol, radiation dosimetry, 540*  
Se-selenochrome uptake, imaging, in animals, 212  
tomography, 158*  

**Aerosol**  
delivery, ultrasonic nebulizer, 707  
*Tc-Fe oxide, preparation, lung ventilation, 122  

**Albumin**  
see also Iodine-125; Iodine-131; Technetium-99m, albumin  
Cu-colloids, preparation, 559*  
radiodinated, tumor uptake, compared to other agents,  
in mice, 525*  

**Alcoholism**  
liver function and biopsy, 433*  
myocardioathy, **Te-phosphates, myocardial imaging, 241  
serum folate test, value, 439  

**Alpha fetoprotein**  
*F-I, preparation, 765*  
radiolmmunoasay, in liver disease, 159*  

**American Board of Nuclear Medicine**  
information, policies, procedures, 328  

**Amerileum-241**  
source, fluorescent thyroid scanning, 17  
source, fluorescent thyroid scanning, radiation hazards, 408  

**Amino acids** see Carbon-11; Carbon-14; Nitrogen-13; Selenium-75  

**Angiotensin**  
radiolmmunoassy, 563*  

**Antibodies** see Immunology; Radioimmunoassay  

**Argon-37**  
ecreation, total body Ca, neutron activation analysis, 529*  

**Arms see Extremities**  

**Artifactual**  
brain imaging, ear, **TcO₂, 305, 1108  
brain, lung, and liver imaging, 229  
fluid flood uniformity correction, 653  

**Audio-visual programs**  
Introduction to Nuclear Medicine Instrumentation, 513  
Radioluclide Angiography, 669  

**Autoradiography**  
bone uptake of *F, **Tc-diphosphonate, 526*  
cellular uptake of **Tc-glucoheptonate and -*dimercapto-
succinic acid, in rats, 536*  
*I*-proteins, antigen detection in spleen, in rabbits, 1025*  
**Tc-glucoheptonate in myocardial infarct, in rats, 203  
**TcO₂ distribution in stomach, in animals, 559*, 756  
**Tc-pyrophosphate, *P-pyrophosphate, *Sr-chloride, in  
rats, 1025*  
**Tc-S colloid, rat lung, 543*  

---

**JOURNAL OF NUCLEAR MEDICINE**

1140
**Bacteria**
*see also Infection*
*Lactobacillus leichmannii*, radiometric vitamin Bl, assay, 538*
radioimmunoassay, 14C-glucose metabolism, 550*

**Beequerel, Henri**, 579

**Bismuth-204**
citrate, production, nuclear parameters, radiation dosimetry, 301

**Bismuth-206**
citrate, production, nuclear parameters, radiation dosimetry, 301

**Bladder**
radiation dose estimates, 566*TcO₄⁻, MIRD, 74
56*TcO₄⁻ cystography, vesicoureteral reflux, 81

**Bleomycin**
*see also Cobalt-57; Copper-67; Indium-111, Bleomycin; Iodine-131*
radioimmunoassay, 550*, 1123*
radiolabeled, tumor uptake, compared to other agents, in mice, 525*

**Blocking dose**
14t-thyroxine plasma clearance curve, 657
14I-iodomethylcholesterol for adrenal imaging, 540*
perchlorate for 56*TcO₄⁻, 528*, 540*

**Blood**
clot, *see Thrombus*
hemoglobinopathy (SO₄), and purpura fulminans,
56*Tc-pyrophosphate bone imaging, 1062
leukocytes, *see Leukocytes*
lymphocytes, cytotoxic activity, peritoneal macrophages,
14Cr, 1124*
platelet aggregation, effect of 14Cr labeling procedure, 73*
platelets, 14C-
56*Tc-S colloid deposition, in animals, 543*
platelets, 131In-, preparation, distribution, uptake by thrombi, in animals, 561*
radioassay for fibrinolytic activity, 539*
red cells, *see Red Blood Cells; Chromium-51; Technetium-99m, red blood cells*
serum binding of 56*Ga-citrate, effect of radiation, in rats, 538*
sickle cell anemia, 163, 184, 852
sickle cell disease, bone marrow scanning, 947*
sickle cell disease, spleen uptake of 56*Tc-diphosphonate, 108

**Bolus see Injection**

**Bone**
Ca, in hyperparathyroidism, photon absorption, 533*
computerized axial tomography, 158*
diphosphonate toxicity, 417
forming and resorbing, 56*Tc-polyphosphate uptake, in rats, 93
fracture, 98, 672*
56*Ga-EDTMP, -DTPMP, preparation, distribution, imaging, in animals, 566*, 1003
metabolism, 56*Tc-, 56*P-pyrophosphate, 56*SrCl₂, autoradiography, in rats, 1025*
metastatic disease, 235*, 253, 433*, 526*, 530*, 755, 764*
mineralization, 14Tetracycline analog studies, in dogs, 549*
osteogenic sarcoma, distribution of 56*P- and 56*Tc-diphosphonate, 548*
osteomyelitis, 71*, 617, 620, 857*
osteoporosis, 526*, 711
56*P- and 56*P-bone agents, distribution, in rats, 548*
56*P-diphosphonate tumor therapy, 548*
56*P-diphosphonate turnover, in dogs, 548*
Paget's disease, 13, 693
Pelligrini-Stieda calcification, 693
rheumatoid arthritis, quantitative 56*Tc-diphosphonate uptake, 525*

Rib image erasure, heart imaging, 56*Tc-phosphates, 68
56*Tc-4-imidodiphosphate, preparation, distribution, in animals, 857*
56*Tc-leukocyte uptake, in rats, 313
56*Tc-pyrophosphate uptake, hydroxyproline in blood and urine, 711
ultrasoundography, 672*
uptake dynamics, 14F, 56*Tc-diphosphonate, in animals, 526*
uptake parameters, 14F and 14Ca, in animals, 549*

**Bone imaging**
causes of abnormalities, 229
facial-mandibular, 56*Tc-agents, 14TI transmission imaging, 525*
facial skeleton, 56*Tc-diphosphonate, 434*
56*Ga-DTPMP, -EDTMP, in dogs, 566*, 1003
in hyperparathyroidism, 56*Tc-pyrophosphate, 533*
infectious, hemoglobinopathy and purpura fulminans, 56*Tc-pyrophosphate, 1060
joint disease, 56*Tc-phosphates, in children, 554*
lepromy, 56*Tc-pyrophosphate, 788
metastatic carcinoma from breast, 56*Tc-polyporphosphate, 235*
metastatic disease pattern, 56*Tc-pyrophosphate, 526*
osteomyelitis, 56*Tc-diphosphonate, in children, 620, 857*
potmenopaosal osteoporosis, 526*
radiation therapy effects, 56*Tc-pyrophosphate, 527*
radii, effect of unilateral pulmonary hypovascularity,
56*Tc-phosphates, 27, 853
staging lung cancer, 529*, 530*
56*Tc-polyporphosphate uptake in nonmalignancy, 693
thyroid acropachy, 56*Tc-pyrophosphate, 791
tooth extraction sockets, 56*Tc-diphosphonate, in rats, 688
total hip arthroplasty, 56*Tc-pyrophosphate, 526*

**Bone scanning**
bone island uptake of 56*Tc-pyrophosphate, 113
breast carcinoma, 14F, 433*, 56*Tc-phosphates, 433*
cold areas, 56*Tc-diphosphonate, 755
comparison of 14F and 56*Tc-polyporphosphate, 98
comparison of 56*Sr and 56*Tc-pyrophosphate kit preparations, 325*
effect of 56*Fe-dextran on uptake of 56*Tc-phosphates, 374
filarial infestation, 56*Tc-diphosphonate, 425
focal renal activity, 56*Tc-polyporphosphate, 426, 427, 428, 429
infarct, serial changes, 184
mastocytosis, 56*Tc-diphosphonate, 699
melorheostosis, 56*Tc-pyrophosphate, 1106
metastatic disease, 56*Tc-pyrophosphate, 253, 526*, 56*Tc-diphosphonate, 755, 764*
osteoblastoma of the axial skeleton, 56*Tc-polyporphosphate, 187
osteomyelitis, 56*Tc-polyporphosphate, 71*, 56*Tc-pyrophosphate, 617
renal failure, 56*Tc-polyporphosphate, 764*
spleen uptake of 56*Tc-diphosphonate, 108
thyroid acropachy, 56*Tc-pyrophosphate, 791
total hip arthroplasty, 56*Sr, 1121*

**Bone marrow**
liposome-trapped 56*Tc-DTPA, distribution, in animals, 1067
osteomyelitis, bone scanning, 71*, 617, 620, 857*
radiation dose estimates, 56*TcO₄⁻, MIRD, 74
scanning, sickle cell disease, 56*Tc-S colloid, 947*

**Book reviews**

*Actualité de Biophysique et de Médecine Nucleaire*, 1023
Administration of a Radiology Department, 945
Basic Nuclear Medicine, 761
Basic Radiation Biology, 856
Beyond Normality: The Predictive Value and Efficiency of Medical Diagnoses, 855
Breast Cancer Diagnosis, 856
Clinical Scintillation Imaging, 761
SUBJECT INDEX

Diagnostic Radiology, A Concise Practical Manual, 155
Diagnostic Ultrasound in Neurology. Methods and Techniques, 761
Elements of Radiation Protection, 1023
Engineering Compendium on Radiation Shielding. Vol. II. Shielding Materials, 1118
Heart and Coronary Arteries, 945
International Encyclopedia of Pharmacology and Therapeutics. Section 79: Sulfur-Containing Radioprotective Agents, 512
Medical Malpractice Law, 669
Medical Neurology, 512
Non-Invasive Brain Imaging: Computed Tomography and Radiouclides, 669
Nuclear Medicine in Clinical Pediatrics, 70
Parathormone and Calcitonin Radioimmunoassays in Various Medical and Osteoarticular Diseases, 1118
Pediatric Nuclear Medicine, 512
Proceedings of the Society of Photo-Optical Instrumentation Engineers. Vol. 46. Image Assessment and Specifications, 155
Proceedings of the Society of Photo-Optical Instrumentation Engineers. Vol. 47. Application of Optical Instrumentation in Medicine, 155
Radioimmunoassay, 855
Radionuclide Studies of the Genitourinary System, 856
Radiopharmaceuticals, 431
Renal Function Evaluation, 945
Synopsis of Gynecologic Oncology, 669
Textbook of Radiology, 762
The Renal Uptake of Radioactive Mercury, ("H2Clu), 855
The Thyroid and Its Diseases, 1118
Bowel see Gastrointestinal tract
Brain
aneurysms, 157*
arteriovenous malformations, 13, 157*
leakage, 157*
blood volume, computerized axial tomography, 1026*
carotid–basilar bypass, in dogs, 948*
cerebral degeneration, 114Tc-DTPA stasis in posterior fossa, 349
epidural hematoma, 972, 975, 977, 986
H2O, cerebrospinal fluid leak, 1122*
131I-antipyrene, kit preparation, 1091
Medical Neurology, book review, 512
18F extraction, 1026*
18F-18F generator, 536*
18F-TcO4, distribution, effect of prior Sn(II) administration, 380
tomography, computerized axial, 1123*
tomography, trauma, 1122*
tumor, metastatic thyroid, post-131I therapy hemorrhage, 307
ultrasonography, craniofasciography, in infant, 327*
ultrasonography, posterior fossa cyst, 766*
ultrasonography through postoperative bone flap, 948*
ultrasonography, book review, 761*
venous anatomy, 114Tc, in normal cadavers, 527*
Brain, blood flow
arterial anastomosis, after surgery, 114Tc, 514*
arterial anastomosis indication, 114Tc, 859*
arteriovenous shunt presenting as AVM, 114TcO4, 1057
audiovisual program review, 669
carotid endarterectomy, 234*
cerebral vascular disease, 157*, 473*, 527*
cerebral vascular disease, 114Tc-microspheres, 114TcO4, 170
cervical lymphadenitis, 114TcO4, 26
cervical venous reflux, 114TcO4, 9
changes, migraine attack, 325*
compared to imaging, 552*
compartmental model, 114Tc, 596
data analysis, 531*; algorithm, 531*
data analysis, positron images, 114Tc, 543*
effect of increased external carotid circulation, 114TcO4, 527*
epidural hematoma, 975, 977
"hot nose" phenomenon, 527*
in dementia, 133Xe, 233*, 763*
intracranial fibromuscular dysplasia, 114TcO4, 190
jugular vein reflux, 61, 225
posterior, 114TcO4, 13
regional, 114Xe, color display, 953
regional, partial seizures, 114Xe, 1122*
stroke, 764*
subarachnoid hemorrhage, intracranial ventricle analysis, in monkeys, 858*
subdural empyema, 980
subdural space lesions, 528*
114TcO4, in children, 780
vertebral artery fistula, 114TcO4, 24
18F, digital model, 159*
114Xe, injection site effects, in baboon, 158*
80-lens oscilloscope camera, 290
Brain imaging
book review, 669
causes of abnormalities, 229
compared to computerized axial tomography, 546*, 552*
differential diagnosis, 114TcO4, 114Tc-diphosphonate, 224
eas" artifact, 114TcO4, 305, 1108
epidural hematoma, 972, 975, 977, 986
114Ga-adenosine triphosphate, 114NH3, 114O2, 473
114Ga-DTPA, multiwire proportional chamber positron camera, 546*
perchlorate blocking dose for 114TcO4, i.v., 528*
renal dialysis patients, 114Tc-DTPA, 6
screening, usefulness, 439
staging lung cancer, 406, 529*, 530*
subdural empyema, 114TcO4, 980
subdural space lesions, 528*
114Tc-glucopentehionate, 345, 786
tumor, comparison of agents, 418, 419
Brain scanning
114Ga-citrate, 114TcO4, in stroke, 764*
meningioma, 114Tc-tyrosinophosphate, -DTPA, 114Ga-citrate, 763*
perinatal asphyxia, 114TcO4, 554*
renal dialysis patient, 114TcO4, 6
subdural hematoma, unoperated, followup, 948*
Brain tomography
Anger scanner, 547*
blood flow, 114Ga-EDTA, 114Kr, 546*
book review, 669
114CO, 493, 552*
comparison to imaging, 552*
epidural hematoma, 972
114Ga-EDTA, 493, 547*, 603
in children, 433*
increased intracranial pressure, 157*
information extraction, 157*
114NH3, 114CO-hemoglobin, 552*, 603
normal, 516*
scintillation camera, computer, 114TcO4, 551*
senile dementia, 516*
transverse section, MGH positron camera, 114NH3, CO2, 551*
tumor, effect of dexamethasone therapy, 114TcO4, 528*
vascular lesions, 157*
Breast
calcifications, 1120*
cancer, lung ventilation, perfusion, lymphangitic carcinomatosis, 114Xe, 114Tc-MAA, 258
cancer, metastatic to bone, 235*, 433*, 764*
cancer, metastatic to liver, 677
cancer staging, book review, 856
cancer, thermography, 672*
Chromatography

*C*-aminocyclopentaneacarboxylic acid, 748

*C*-octylamine, 752

*C*-citric acid, 554*•
eighteen radiopharmaceuticals, 911

**Ga-DTPMP, -DTPMP, 1003

**I*-plasminogen, 542*

**I*-rose bengal, 36

**I*-tetracyclines, 274

radiochemical purity, 865

**Se-selenocholesterol, 212

**Tc-Bioquin-7CA, 907

**Tc*-Fe oxide, 122

**Tc-HSA, 46, 537*, 758

**Tc*-hydroxyquinoline carboxylate, 907

**Tc*-iminodiacetic acid analogs, 633

**Tc*-kethoxal-bis(thiosemicarbazone), 816

**Tc*-leukocytes, 313

**Tc*-penicillamine complexes, 810

**Tc*-pyridoxylidene glutamate, 36, 555*

**Tc*-pyrophosphate, 918

**Tc*-streptokinase, 226, 227

unbound **Tc* in water-soluble agents, 758, 805, 820

Chromium-51

c-chromate, Limulus test, 1088

-leukocytes, labeling, 480

-leukocytes, distribution, in rats, 313

-lymphoma cells, cytotoxicity assay, 1123*

package wipe testing, 1013

-platelets, aggregation, 73*

-platelets, **Tc*-S colloid lung deposition mechanism, in animals, 543*

-RBC, disappearance studies, 1113

-RBC, fecal blood loss, 1053

-RBC, lung scan, Goodpasture's syndrome, 702

-RBC, spleen scan, sickle cell anemia, 852

-peritoneal macrophages, cytotoxic activity of immune lymphocytes, 1124*

Cisternography

see also Ventriculogram

cerebrospinal fluid leak, **Tc*-HSA, 797

dynamic, **In-DTPA, 838*
effects of pneumoencephalography, **In-DTPA, 54

focal activity, **Tc*-HSA, 626

head injuries, 233*

infusion tests, puncture site leakage, 65

spinal descent, **Tc*-HSA, 763*

stasis in posterior fossa, **In-DTPA, 349

transverse section, **In-DTPA, 924

uptake in a subdural hygroma, 119

Clinical evaluation

alpha-fetoprotein radioimmunoassay in liver disease, 473 cases, 159*

Anger tomographic scanner, brain, 210 cases, 547*

arterial anastomosis, 65 cases, 86*

bolus injection technique, 135 cases, 564*

bone imaging for metastatic disease, **Tc*-pyrophosphate, 62 cases, 526*

bone imaging in breast cancer, **Tc*-polyphosphate, 174 cases, 235*

bone scanning, comparison of **F and **Tc*-polyphosphate, 50 cases, 98

bone scanning for metastatic disease, **Tc*-diphosphonate, 259 cases, 764*

bone scanning in breast carcinoma, **F, 50 cases, 433*

**Br distribution in cerebrospinal fluid in tuberculous meningitis, 163 cases, 545*

brain blood flow, **Tc*-HSA, 1051 children, 780

brain blood flow, tomography, **Ga-EDTA, **Kr, 50 cases, 546*

brain blood flow, vascular disease, 295 cases, 527*

brain blood flow, vascular disease, **Tc*-microspheres, 56 cases, 170

brain scanning, dynamic–static, chronic subdural space lesions, 111 cases, 528*

brain scanning in perinatal asphyxia, **Tc*-HSA, 92 cases, 554*

brain tomography, 207 children, 433*

brain tomography compared to imaging, **Tc*-HSA, 635 cases, 552*; 770 cases, 546*

brain tomography, normal brain, 2500 cases, 516*

carotid endarterectomy, 104 cases, 234*

CEA radioimmunoassay, bronchogenic carcinoma, chronic bronchitis, 74 cases, 672*

CEA radioimmunoassay, screening test, 956 cases, 236*

cisternography in head injuries, 140 cases, 233*

**Co-bleomycin tumor imaging, 80 cases, 529*

cystography, vesicoureteral reflux, **Tc*-HSA, 137 cases, 81

DNA radioimmunoassay in cancer, 173 cases, 550*

facial-mandibular imaging, **Tc* bone agents, **Tl* transmission imaging, 88 cases, 552*

**Ga-citrate scanning, bowel preparation, 200 cases, 559*

gastroesophageal reflux imaging, **Tc*-S colloid, therapy effects, 50 cases, 559*

GI tract imaging, Meckel's diverticulum, **Tc*-HSA, 114 children, 553*; 52 children, 553*; 170 children, 553*; 100 cases, 465

heart blood flow, time–activity function recovery, 52 cases, 557*

heart imaging, acute infarct, **Tc*-pyrophosphate, 140 cases, 523*

heart imaging, subendocardial infarct, **Tc*-pyrophosphate, 51 cases, 523*

heart imaging, rest and stress, **Tl* TI, 63 cases, 522*

heart imaging, **Tc*-pyrophosphate, 50 cases, 946*; 75 cases, 523*

heart imaging, **Tl*, acute infarct, 200 cases, 523*

heart, left-to-right shunt quantitation, 105 cases, 857*

heart, left ventricular ejection fraction, first transit **Tc*-albumin, 55 cases, 556*

heart, left ventricular performance, postmyocardial infarct, radionuclide angiography and ultrasound, 61 cases, 671*

**I* thyroid therapy, long-term followup, 233 cases, 672*

**I*-thyroid uptake, comparison of liquid and capsule, 125 cases, 310

kidney imaging after brain imaging, **Tc*-glucoaldehydeonate, 200 cases, 786

kidney imaging, renin radioimmunoassay and Saralasin infusion tests, 162 cases, 562*

kidney, renograms in hypertension, 50 cases, 947*

kidney to aortic bloodflow index, 116 cases, 537*

kidney transplant evaluation, **F-, **I*-fibrinogen, **Tc*-S colloid, **Ga-citrated, 59 cases, 175

kidney transplant evaluation, **Tc*-S colloid, 45 cases, 181

liver angiography, scanning, in tumor, **Tc*-S colloid, 118 cases, 434*

liver imaging, metastases, **Tc*-S colloid, 275 cases, 677

liver scanning compared to imaging, 125 cases, 419, 421

liver tumor diagnosis, angiography, **Tc*-S colloid scan, laparotomy, 118 cases, 671*

lung image interpretation, effect of ventilation image, 500 cases, 531*

lung imaging, pulmonary embolism, 97 cases, 163

lung scanning in infection, **Ga, 70 cases, 540*

lung ventilation, half-time distribution images, 100 cases, 88

lung ventilation, perfusion, **Kr, **Tc*-microspheres, 80 cases, 530*
lung ventilation, perfusion, regional, ¹³¹Xe, instrumentation, 50 normals, 337
lung ventilation, perfusion, ¹³¹Xe, in pulmonary embolism, 105 cases, 613
splanchnogely, differential diagnosis, ultrasound, 60 cases, 1124*
thermography, breast cancer, 239 cases, 672*
thrombus scanning, ¹⁸³Tc-MAA, 52 cases, 563*
thyroid cancer, surgery, ¹³¹I therapy, medication, followup, 576 cases, 532*
thyroid, cold nodule, ultrasound, thermography, 61 cases, 326*
tomography, computerized transaxial, brain, 117 cases, 1123*

¹³¹T, kit, 57 cases, 321
¹³¹T, T, simultaneous, 54 cases, 660
ultrasoundography, renal transplants, 432*
ultrasoundography, mass diagnosis, 100 children, 766*
ultrasoundography, normal bone, 666 cases, 672*
-bleomycin, Limulus test, 1088
-bleomycin, radioimmunoassay, 550*
-bleomycin, tumor studies, 529*
-bleomycin, tumor uptake, compared to "Co-chloride, in animals, 567*
-DTPA-fatty acids, preparation, distribution, in animals, 565*
package wipe testing, 1013
scintillation-camera field flood uniformity, 653
vitamin B₁₂, radioassay, toadfish serum binder, 737

Cobalt-58
vitamin B₁₂ absorption, in celiac disease, small bowel resection, 235*

Cobalt-60
package wipe testing, 1013
radioassay, liquid scintillation counter, 434*

Collimator
 coded aperture, noise analysis, 528*
large-field scintillation camera, performance study, 546*
myocardial imaging, 142, 401, 522*, 523*, 583, 719, 880
parallel hole, optimizing design, 236*
pinhole, compared to coded aperture, 528*
system for germanium semiconductor array, 528*
tantalum, scintillation camera, 50

Colloid
 see also Indium-¹¹³m; Technetium-⁹⁹m; Technetium-⁹⁹m, sulfur colloid
artificial lipid vesicles, interaction with protein and mammalian cells, 567*
liposome and vesicle labeling, 1102
liposome trapped ¹⁸⁵Tc-DTPA, preparation, distribution, in animals, 1067

Computer
 see also Camera, scintillation; Data processing; Tomography, computerized axial
attenuation effects in tomography, ¹⁷⁷Tc and positron emitters, 552*
background subtraction, ¹⁸⁵Tl heart imaging, 744
bloodflow effects on renogram, ¹⁷⁷Tc-DTPA, ¹⁷⁷I-Hip-puran, 537*
cerebral flow analysis, 531*: algorithm, 531*
deconvolution analysis, dynamic ¹⁷⁷Tc-DTPA renal scan, 352
dynamic lung perfusion imaging, 541*
gating procedure, 297
germanium semiconductor array scanner, 528*
heart imaging, rib erasure, ¹⁷⁷Tc-phosphates, 68, 523*
image enhancement, scintillation camera, Fourier transform, 647
model for bone uptake of ¹³¹I and "Ca, 549*
modular system, 544*
positron brain perfusion data analysis, 543*
-probe, left ventricular function studies, 557*
quantitative myocardial scanning, ¹⁷⁷Tl, 531*

regional liver perfusion, focal lesions, first pass ¹⁷⁷Tc-S colloid, 532*
system, regional lung ventilation, ¹³¹Xe, 337
tomographic scanner, flying spot x-ray microbeam, 551*
tomography, image generation and display, 515*
tomography, positron transaxial, 552*
tomography, transverse, brain, vascular lesions, 157*
ventricular contraction patterns, edge delineation, 544*

Copper-⁶²
⁶²Zn-⁶⁷Cu generator, nuclear parameters, radiopharmaceutical preparations, 559*

Copper-⁶⁴
 liver kinetics in Wilson's disease, 235*
thiosemicarbazone analog for tumor, distribution, in mice, 568*

Copper-⁶⁷
-bleomycin, -chloride, tumor uptake, in animals, 567*

Cyclotron
¹⁰⁵Rh preparation, 536*

Data processing
 see also Computer
background subtraction, heart studies, ¹⁸¹Tl, 740
cardiocam chamber flow/volume characteristics, 84, 940, 941
cerebral blood flow, ¹³¹Xe, color display, 953
deconvolution analysis, ¹⁷⁷Tc-DTPA renogram, 352, 1020
digital low-pass filtering, 844
digital, zone plate camera, 326*
ECG gating, 297
detox delineation of left ventricular contraction patterns, 544*
left ventricular function, mobile dual probe, 930
lung ventilation, half-time distribution images, ¹³¹Xe, 88
modular system, 544*
pocket calculator, 544*
radioimmunoassay curve fitting, 549*
simultaneous ⁷ⁱGa-citrate, ¹⁷⁷Tc-S colloid liver scans, 369
subtraction, cerebral blood volume, computerized axial tomography, 1020*

Data storage
long-distance image transmission, 394

Deadtime
scintillation camera, 665; correction, 137

Detector
 crystal mosaic, scintillation camera, 1008
germanium semiconductor array, 528*
zone plate aperture, imaging processing, 326*

Diaphragm
 congenital hernia, liver image, ¹⁷⁷Tc-S colloid, 110

Digoxin
 see also Radioimmunoassay
 assay, screening test, 439

Diphosphonate see Calcium-⁴⁵; Phosphorous-³²; Phosphorous-³³; Technetium-⁹⁹m, diphosphonate

Display
 color, cerebral flow analysis, 531*, 953
computerized tomography, 515*
direct recording on 4x5-in. film, 937
eight-level system, 857*
long-distance image transmission, 394
80 lens oscilloscope camera, 290

DNA
 radioimmunoassay, in cancer, 550*

Dose
 see also Radiation dosimetry
radiopharmaceutical, record keeping, 1015

Dose calibrator
 ³¹P assay, 404, 1109, 1110

Drug abuse
 cross-reacting cannabinoids in urine, radioimmunoassay, 326*

DTPA see Cobalt-⁵⁷; Copper-⁶²; Gallium-⁶⁸; Hydrogen-³; Indium-¹¹¹, DTPA; Technetium-⁹⁹m, DTPA
EDTA see Copper-62; Gallium-68

Education
American Board of Nuclear Medicine certification, 328

Enzyme
inhibitors, adrenal, H+, R-1, preparation, distribution, in dogs, 525*, 998
oxidative phosphorylation, in vitro, H+, 0, 558*
serum, compared to heart imaging, 523*, 524*
serum levels, myocardial infarct, 1024*
serum levels, myocardial infarct sizing, in dogs, 534*
Sn-induced, in vivo ~Tc red cell binding, 941

Extremities
see also Joint; Thrombus
bone image in hemoglobinopathy and purpura fulminans, ~Tc-pyrophosphate, 1062
hand blood flow, ~Tc-RBC, Raynaud's phenomenon, 564*
hand, Na turnover, neutron activation analysis, 724
injection technique, effect on bolus, 564*
legs, exercise testing, occlusive artery disease, ultrasound, 18Xe clearance, 433*
legs, thrombus imaging, ~Tc-MAA, -microspheres, 969
legs, thrombus scanning, 563*, 564*
metastatic disease on bone scan, incidence, 755

Eye
ultrasonography, 327*, 1124*

Fatty acids
14C-, i-hexadecanoic acid, myocardial infarct, in dogs, 1077
14C-pyruvate, myocardial infarct, in rats, 1077
14CO2, H+, -DTPA, preparation, distribution, in animals, 565*
111m-hexadecanoic acid, heart imaging, 535*

FDA
central radiopharmacies, 577

Fetus
131I thyroid therapy, fertility of ex-patients, 460, 532*
131I thyroid therapy in pregnancy, 146
pelvimetry, usefulness, 439
placental blood flow and growth retardation, ~Tc-HSA, 72*
radiation dose estimates, 181I, 515*, ~Tc, 111In, 131mIn, 131I, 181Xe, 539*, 836
ultrasonography, 516*, 517*, 860*, 1028*

Fibrin
radioassay for fibrinolytic activity, 539*
radioiodo-, fibrinolytic and thromboembolic activity of tumors, in vitro, 566*

Fibrinogen
see also Iodine-125, fibrinogen; Iodine-131; Mercury-197; Technetium-99m
radioiodo-, fibrinolytic activity of tumor, in vitro, 566*
radioiodo-, tumor uptake, compared to other agents, in mice, 525*
radioiodo-, tumor uptake mechanism, in animals, 567*

Film
4x5 inch, direct scan recording, 937

Filter
Millipore, 60Ga retention, 852

Fluorescence scanning
thyroid, 68Am source, radiation hazards, 408
thyroid, benign and malignant nodule differentiation, 17

Fluorine-18
bone scanning, compared to ~Tc-polyphosphate, 98
bone scanning in breast carcinoma, 433*
bone uptake dynamics, in animals, 526*
bone uptake, mathematical model, 549*
-DAST, fluorinating agent, preparation, 558*
leukocyte labeling, 480
positron camera resolution, 757

Full width at half maximum
positron camera, 757
positron transaxial tomograph, 493

scintillation camera collimators, 50, 665
scintillation camera, collimator, 6K, 60Tc, 61I, 60TI, 719

Gallbladder
131I-indotricarbocyanines, preparation, distribution, in mice, 524*
123I-lodocholesterol uptake during adrenal scanning, 33
11In-phenolphthaehxam, preparation, distribution, in animals, 562*
jaundice, differential diagnosis, ~Tc-HIDA transport and ultrasonography, 545*
jaundice evaluation, 159*
~Tc-EDDA analogs, preparation, distribution, in animals, 565*

~Tc-HIDA, preparation, distribution, in animals, 537*, 545*, 633
~Tc-hydroxyquinolinecarboxylate, preparation, distribution, in animals, 907
~Tc-kethoxal-bis(thiosemiarbazone), preparation, distribution, in animals, 816
~Tc-penicillamine complex, preparation, distribution, in animals, 810
~Tc-pyridoxyldenediglutaminate, 123I-rose bengal, comparison, 36
~Tc-pyridoxyldenediglutaminate, quality control, studies in children, 555*
ultrasonography, 545*, 673*, 860*

Gallium-67
-chloride, -lactate, -Fe-DTPA, brain tumor imaging, 418, 419
leukocytes, abscess imaging, 434*
nuclear parameters, 369
parotid uptake, Sjogren's syndrome, 530*

Gallium-67, citrate
abdominal abscess scanning, with ultrasound, 545*
abscess imaging, perinephric, 858*
abscess uptake, effect of Fe dextran, in rabbits, 356
abscess uptake, in rats, 800
brain scan in stroke, 764*
brain scan, meningioma, 763*
brain tumor imaging, 418, 419
breast and milk uptake, 223, 1055*
brain imaging, 223
comparison of dual-probe scanner and large-field scintillation camera, 547*
hepatoma uptake, compared to other agents, in rats, 274
inflammatory process scanning, 671*
joint imaging, in children, 554*
Kaposi sarcoma scanning, 947*
kidney scanning, 872
kidney transplant evaluation, 175
kidney uptake in amyloidosis, 899
leukocyte labeling, Fe effect, 852
Limulus test, 1088
liver imaging, actinomycosis, 947*
liver imaging, hemangioma, 362
liver scanning, tumor, simultaneous ~Tc-S colloid, 369
lung cancer staging, 529*
lung scanning in infection, 540*; quantitative, 540*
malignant fibrous histiocytoma scan, 630
pulmonary artery sarcoma imaging, 893
salivary gland uptake after radiation therapy, 685
scanning, bowel preparation, 559*
scanning, causes of abnormalities, 229
scanning in breast cancer, book review, 856
serum binding, effect of radiation exposure, in rats, 538*
thyroid scanning, 268
tuberculous peritonitis scan, 272, 1020

thyroid imaging, compared to 123I-bleomycin, 671* tumor scanning, in children, 1026*
tumor uptake, compared to fibrinogen, bleomycins, albumin, 525*
take by regenerating liver, in rats, 226
urinary tract infection imaging, 1025*

INDEX

1146 JOURNAL OF NUCLEAR MEDICINE
Gallium-68
-adenosine triphosphate, brain imaging, 473
-albumin microspheres, preparation, distribution, in dogs, 57
-brain perfusion, data analysis, 544*
-DTPA, brain, multiwire proportional chamber positron camera, 546*
-EDTA, brain blood flow, tomography, 546*
-EDTA, brain tomography, 493, 547*, 603
-EDTMP, -DTPMP, chelates for bone, preparation, distribution, imaging, in animals, 566*, 1003
-nuclear parameters, 57
-posterior camera resolution, 757
-radiopharmaceutical preparation, 227

Gastrin
radioimmunoassay, 434*

Gastrointestinal tract
bowel loop concentration of **TcO₂⁻, 470
bowel preparation, "Ga-citrate scanning, 559*
¹C-¹C-glycine, -glycine cholate metabolism, breath test, 551*
colon cancer, metastatic to liver, 677
-displacement, epidermoid cyst of spleen, 196
-fecal blood loss, ⁶⁷⁷₅Cr-RBC, 1053
gastroesophageal reflux, effect of treatment, **Tc-S colloid imaging, 559*
-Meckel's diverticulum, **TcO₂⁻ imaging, in children, 465, 553*
radiation dose estimates, **TcO₂⁻, MIRD, 74
-Schilling test, 229
**Tc-HIDA transport, in jaundice, 545*
**TcO₂⁻ secretion site, 559*, 756
-visceral larva migrans, radioimmunoassay, 236*
-vitamin B₁₂ absorption, dual-isotope kit, ⁶⁷⁷₅Co-B₁₂, ⁶⁷⁷₅Co-B₁₂, 72*
**Xe clearance, in dogs, 235*

Gating, ECG see Heart, blood flow

Generator
**Mo-m**₅₇Tc, contaminants, 158*, 840
**⁶⁷⁷₅O₂-**⁶⁷⁷₅S, **⁶⁷⁷₅O₂-**⁶⁷⁷₅I, 555*
**⁶⁷⁷₅Rb-**⁶⁷⁷₅Kr, 530*, 535*
**⁶⁷⁷₅Sr-**⁶⁷⁷₅Rb, 536*
**⁶⁷⁷₅ZN-**⁶⁷⁷₅Cu, 559*

Glomerular filtration rate see Kidney

Gold-198
-clearance rate by RES, 449
-false-positive liver scan in hepatic amyloidosis, 31
-Limulus test, 1088
-package wipe testing, 1013
-radiation effect on carcinogenesis, in rats, 715

Goodpasture's syndrome
**⁶⁷⁷₅Cr-RBC, **⁶⁷⁷₅Fe studies, 702

Heart
and coronary arteries, book review, 945
**⁶⁷⁷₅CO₂- **⁶⁷⁷₅HDTMP-fatty acids, preparation, distribution, in animals, 565*
disease, lung ventilation and perfusion, 530*
disease, myoglobin radioimmunoassay, 765*
-left ventricular contraction patterns, edge delineation, 544*
-myocardial damage site uptake of 18 radiopharmaceuticals, 911
-myocardial infarct, rat model, 203
-myocardial infarct uptake, ¹¹⁷²In-, **⁶⁷⁷₅Tc-EDTMP, in dogs, 508
-myocardial infarct mechanism, **⁶⁷⁷₅Tc-diphosphonate, -pyrophosphate, in dogs, 534*; in vitro fetal mouse, 534*
-myocardial infarct uptake mechanism, **⁶⁷⁷₅Tc-pyrophosphate, -tetracycline, in rabbits, 639
-myocardial infarct uptake, **⁶⁷⁷₅Tc-agents and **⁶⁷⁷₅Sr, in rabbits, 534*
-myocardial infarct uptake, **⁶⁷⁷₅Tl, **⁶⁷⁷₅K, effect of cardiac drugs, in dogs, 535*
**⁶⁷⁷₅Rb, **⁶⁷⁷₅K, coincidence and noncoincidence counting, 153, 154
-right atrial myxoma, 890
-scanning, **⁶⁷⁷₅Tl, quantitative, 531*
**⁶⁷⁷₅Sr-**⁶⁷⁷₅Rb generator, 536*
**⁶⁷⁷₅Tc-diphosphonate uptake in renal failure, 896
**⁶⁷⁷₅Tc-pyrophosphate uptake, 853, 854
**⁶⁷⁷₅Tc-tetracycline, preparation, distribution, in rats, 432*
tomography, **⁶⁷⁷₅NH₃, 493
tomography, **⁶⁷⁷₅NH₃, **⁶⁷⁷₅CO-hemoglobin, 552*, 603
tomography, **⁶⁷⁷₅Rb, **⁶⁷⁷₅Cs, **⁶⁷⁷₅NH₃, 547*
tomography, transverse section, **⁶⁷⁷₅Cs, **⁶⁷⁷₅Tl, **⁶⁷⁷₅Se-selenomethionine, 552*
tomography, x-ray, 158*

Heart, blood flow
-audiovisual program review, 669
-bronchopulmonary sequestration, **⁶⁷⁷₅TcO₂⁻, in children, 1035
cardiac output, effect of hypoxia, **⁶⁷⁷₅Ce-microspheres, in dogs, 542*
-continuous imaging, **⁶⁷⁷₅Kr infusion, 535*
coronary, **⁶⁷⁷₅Xe myocardial clearance, in dogs, 1044
d-transportation of the great arteries, **⁶⁷⁷₅Tc, in children, 554*
-flow/volume characteristics, **⁶⁷⁷₅TcO₂⁻, 84, 940, 941
gating, 297, 555*, 556*, 557*, 1024*
**⁶⁷⁷₅Ir, generator, studies in monkeys, 555*
-left and right cardiac output, unusual anatomy, 623
-left-to-right shunt detection, CO₂ inhalation, in children, 555*
-left-to-right shunt quantitation, 857*
-left ventricular ejection fraction, count rate, 557*
-left ventricular ejection fraction, first-pass **⁶⁷⁷₅Tc, 555*, 556*
-left ventricular ejection fraction, frame rate selection, 556*
-left ventricular ejection fraction, nuclear stethoscope, 557*
-left ventricular ejection fraction, reproducibility, 556*
-left ventricular ejection velocity, first-pass, 556*
-left ventricular function, mobile dual probe, **⁶⁷⁷₅Tc-HSA, 930
-left ventricular mean fiber-shortening velocity, systolic ejection rate, **⁶⁷⁷₅TcO₂⁻, 857*
-left ventricular volume, probe minicomputer, 557*
-myocardial infarct, **⁶⁷⁷₅TI, 233*
-patent ductus arteriosus, **⁶⁷⁷₅TcO₂⁻, 554*
-quantitative imaging, **⁶⁷⁷₅H-heptadecanoic acid, 535*
-radionuclide and ultrasondb, post-myocardial infarct, 671*
-sciillation-camera region-of-interest crosstalk, 557*
**⁶⁷⁷₅Tc-RBC, tagged in vitro, 565*
-80-lens oscilloscope camera, **⁶⁷⁷₅Tc-HSA, 290

Heart imaging
-acute infarct, dual isotope, **⁶⁷⁷₅Tl, **⁶⁷⁷₅Tc-pyrophosphate, 524*
-acute infarct, **⁶⁷⁷₅Tc-polyphosphate, 524*
-acute infarct, **⁶⁷⁷₅Tc-pyrophosphate, 523*
-acute infarct, **⁶⁷⁷₅Tl, time of study, 523*
-arteriosclerosis, myocardiopathy, **⁶⁷⁷₅Tc-pyrophosphate, **⁶⁷⁷₅pyrophosphate, 241
-background subtraction, **⁶⁷⁷₅Tc-phosphates, 68
-background subtraction, **⁶⁷⁷₅Tl, 744
-collimation, **⁶⁷⁷₅Cs, **⁶⁷⁷₅K, **⁶⁷⁷₅Rb, **⁶⁷⁷₅Ir, 401
collimation, **⁶⁷⁷₅K, **⁶⁷⁷₅Tc, **⁶⁷⁷₅Tl, 719
compared to electrocardiography, 522*, 523*, 524*, 534*
-comparison of **⁶⁷⁷₅TI, **⁶⁷⁷₅Cs, **⁶⁷⁷₅K, **⁶⁷⁷₅Rb, in dogs, 880
-comparison of **⁶⁷⁷₅Tl and **⁶⁷⁷₅Tc-diphosphonate, myocardial infarct, in dogs, 534*
infarct, **⁶⁷⁷₅H-heptadecanoic acid, **⁶⁷⁷₅K, **⁶⁷⁷₅C-heptadecanoic acid, in dogs, 1077
SUBJECT INDEX

infarct, post surgery, 1148
infarct quantitation, 1148
infarct sizing, 1148
infarct, 1148
infarct uptake mechanism, 1148

Hormone
see also Thyroid-Stimulating Hormone
antithyroglobulin radioimmunoassay, 1148
calcitonin radioimmunoassay in thyroid disease, 1148
follicle-stimulating, radioreceptor assay, 1148
human chorionic gonadotrophin, effect on TSH, 1148
Thyroid Stimulation, 1148

Hydrogen-3
-adrenal enzyme inhibitors, preparation, distribution, in dogs, 1148
-catecholamine metabolism in cerebral ischemia, in gerbils, 1148
-diphosphonate, myocardial infarct uptake mechanisms, in dogs, 1148
-DTPA-fatty acids, preparation, distribution, 1148
-methylxophosphate, radioimmunoassay, 1148
package wipe testing, 1148
quenching curves, 1148
-tetracycline, myocardial infarct uptake mechanism, in rabbits, 1148
-thymidine, radiometric assay for Herpes simplex virus in cell culture, 1148

Immunology
see also Radioimmunoassay
antigens and antibodies in spleen, in rabbits, 1148
-cytotoxic activity of immune lymphocytes against 19Cr-peritoneal macrophages, 1148
-IgG, IgM, IgA, tumor antibodies, tumor uptake, in animals, 1148
-Tc-microaggregated albumin after MAA immunization, in rats, 1148

Indium-111
-chloride, brain tumor imaging, 1148
-ENDA-HSA, preparation, distribution, 1148
-leukocyte labeling, 1148
-leukocytes, distribution, abscess uptake, in dogs, 1148
-package wipe testing, 1148
-phenolxylhaexon, for gallbladder, preparation, distribution, in animals, 1148
-platelets, preparation, uptake in vascular damage sites, 1148
 radiation dose estimates to the embryo, 1148
-summarization peaks, 1148
-transferin, pulmonary vascular permeability, in sheep, 1148

Indium-111, bleomycin
brain tumor imaging, 1148
comparison of dual-probe and tomographic scanners, 1148
Kaposi sarcoma scanning, 1148
liposome and leukocyte labeling, 1148
liver uptake, effect of dimercuraprotin, in mice, 1148
liver imaging, compared to 11Ga-citrate, 1148

Indium-111, DTPA
cisternography, effect of pneumoencephalography, 1148
cisternography, uptake in a subdural hygroma, 1148

Indium-113m
-colloid, liver-spleen imaging in cystic fibrosis, 1148
-colloid, liver-spleen scan, sickle cell anemia, 1148
-ENDTMP, preparation, myocardial infarct uptake, in dogs, 1148
package wipe testing, 1148
radiation dose estimates to the embryo, 1148
radiation effect on cisticercosis, in rats, 1148

Infection
see also Abcesses; Bacteria; Virus
Actinomycetes, 11Ga-citrate imaging, 1148
Ga-citrate scanning, 1148
lung, 11Ga scanning, 1148
osseomysitis, 11Ga, 1171, 1172, 1173, 1174
pelvic masses, ultrasonography, 1148

Injection
middle cerebral artery, 11In, cerebral blood flow, in animals, 1148
percutaneous puncture, ultrasound-guided, 1148
systemic, 11In, coronary blood flow, in dogs, 1148
technique, effect on bolus, 1148

Insulin
adipose tissue binding, effect of fenfuramine, 1148
radioimmunoassay, effect of thyroid hormone, 1148

Interpretation see Observer interpretation

Iodine
content, thyroid nodule, benign and malignant differentiation, fluorescence scanning, 1148
radio-, fibrinogen, fibrin, thrombolytic and fibrinolytic activity of tumors, in vitro, 1148
radio-, fibrinogen, tumor uptake mechanism, in animals, 1148

Iodine-123
assay, coincidence-counting, 1111, 1112
assay, well counter, summing effects, 1120, 1121, 1122
collimation for myocardial imaging, 1120
-fibrinogen, optimal thrombus detection, 1120
-hexadecanoic acid, myocardial infarct imaging, in dogs, 1120
-hexadecanoic acid, quantitative myocardial imaging, 1120
-iodoantipyrine, kit preparation, 1120
leukocyte labeling, 1120
nuclear parameters, 1120
package wipe testing, 1120
radiation dose estimates to the embryo, 1120

Iodine-125
-adrenal enzyme inhibitors, preparation, distribution, in dogs, 1125
-antithyroglobulin, -TSH, binding by lipid vesicles, 1125
-digoxin, radioimmunoassay, kit comparisons, 1125
-DNA, radioimmunoassay, in cancer, 1125
-erythropoietin, radioimmunoassay, 1125
-folic acid-stimulating hormone, radioreceptor assay, 1125
hepatitis B radioimmunoassay, 1125

11l contamination, 1125
Iodine-125
-adrenal enzyme inhibitors, preparation, distribution, in dogs, 1125
-antithyroglobulin, -TSH, binding by lipid vesicles, 1125
-digoxin, radioimmunoassay, kit comparisons, 1125
-DNA, radioimmunoassay, in cancer, 1125
-erythropoietin, radioimmunoassay, 1125
-folic acid-stimulating hormone, radioreceptor assay, 1125
hepatitis B radioimmunoassay, 1125
Iodine-131, uptake by forming and preformed thrombi, in rabbits, 543
Iodine-128, uptake by surface of artery, in vitro, in dogs, 234
-hydroxymercurifluorescein, damaged myocardium uptake, in animals, 911
insulin, adipose tissue binding, effect of fenfluramine, 326
-insulin, radioreceptor assay, 859
-ithalamate, GFR, compared to inulin, **Tc-DTPA, in dogs, 317
metabolism in gram-negative septicemia, in rats, 104
myoglobin radioimmunoadsay, 765
nuclear parameters, 261
package wipe testing, 1013
photon densitometry, in osteoporosis, 526
prolactin radioimmunoadsay, 1027
-proteins, immunology studies of spleen, in rabbits, 1025
radioassay, liquid scintillation counter, 434
-rat alpha fetoprotein preparation, 765
summation peaks, 943, 944
tetacycline analog, bone growth, in dogs, 549
-thyroxine, plasma clearance, effect of blocking, 657
-tumor antibodies, preparation, distribution, in animals, 567
-T, radioimmunoadsay, 411
-T, simultaneous **T,T, radioimmunoadsay, 550, 660
Iodine-125, fibrinogen
clearance rates, 282
endothelial damage sites, in dogs, 543
joint uptake in venography, 1025
kidney transplant evaluation, 175
lung deposition following endotoxin, in animals, 543
-thrombus scanning, 325
-uptake by forming and preformed thrombi, in rabbits, 543
-uptake by thrombi after hip surgery, 71
Iodine-126
**I contamination, 740
Iodine-130
**I contamination, 740
Iodine-131
-albumin, brain tumor imaging, 418, 419
-albumin, extraction efficiency, dual isotope technique, **Tl, **Hg-chloromerodrin, in dogs, 538
-albumin, microaggregated, ultrasona preparation, distribution, in animals, 72
-bleomycin, adenocarcinoma uptake, in rats, 385
-Bromsulphalein, Limulus test, 1088
-contaminant, **Tc generator eluate, 840
-fibrinogen, high specific activity, preparation, thrombus imaging, in dogs, 397
-fibrinogen, kidney transplant evaluation, 175
-hippurate, relative renal blood flow, in dogs, 538*
-**I contamination, 740
-indocarbocyanines for gallbladder, preparation, distribution, in mice, 524
-iodocholestero, adrenal scanning, gallbladder uptake, 33
-iodomethylchlolestero, liver scan, metastases from adrenal carcinoma, 904
-iodomethylnorcholesterol, radiation dosimetry, 540
-leukocyte labeling, 480, 488
-microaggregated albumin, leukocyte labeling, 488
-nor-iodocholestero, adrenal imaging, 563
-nuclear parameters, 261
-orthocholestero, adrenal scanning in renovascular hypertension, 378
-package wipe testing, 1013
-plasminogen, thrombus uptake, in dogs, 542
-PVP, Limulus test, 1088
radiation dose estimates to the embryo, 539*, 515*, 836
radioassay, liquid scintillation counter, 434
-tetacycline, preparation, hepatoma uptake, compared to other agents, in rats, 274
thyroid, autonomous functioning nodule uptake, 532
thyroid carcinoma, disparate uptake, **TcO, 22
thyroid content, grazing animals, during nuclear tests, 515
thyroid scanning, 983
thyroid scanning, "owl eye" sign in carcinoma nodule, 985
thyroid therapy, see Therapy
thyroid uptake, liquid, capsule comparison, 310
thyroid uptake, scintillation camera, 359
-tumor antibodies, preparation, distribution, in animals, 567
-T, simultaneous T, 550*, 660
Iodine-131, Hippuran
-iodide, -PVP, Limulus test, 1088
isolated dog kidney renography, 1121
kidney studies in hypertension, 562
renogram, bloodflow effects, 537
renogram, transplants, 537
Iodine-131, rose bengal
compared to **Tc-pyridoxilenediglutamate for gallbladder, 36
damaged myocardium uptake, in animals, 91
jaundice evaluation, 159
Limulus test, 1088
scan in hepatic adenoma, 560
Iridium-191
generator, heart studies, in monkeys, 555
Iron-59
-chloride, Limulus test, 1088
kinetics, Goodpasture's syndrome, 702
package wipe testing, 1013
Joint
disease, uptake of **I-fibrinogen venography, 1025
disease, **F and **Tc-polyphosphate bone scanning, 98
**Ga-citrate imaging, in children, 554
-mandibular, **Tc-bone agent and **Tl transmission imaging, 525
-quantitative **Tc-diphosphonate uptake in rheumatoid arthritis, 525
**Tc-diposphonate imaging in juvenile rheumatoid arthritis, 554
-total hip arthroplasty, **Sr, 1121
-total hip arthroplasty, **Tc-pyrophosphate evaluation, 526
Kidney
abscess, **Ga-citrate, **Tc-glucocetinate imaging, subtraction method, 858
angiotensin-I radioimmunoadsay in hypertension, bed rest effects, 563
-Citic acid, preparation, distribution, in animals, 558
cellular uptake, of **Tc-glucocetinate and -DMSA, autoradiography, in rats, 536
-Cu agents, preparation, 559
dialysis, abnormal brain studies, 6
disease, effects on bone imaging, 229
disease, effect on Schilling test, 229
extraction efficiency, dual isotope, **I-HSA, **Hg-chloromerodrin, **Tl, in dogs, 538
-failure, **Tc-polyphosphate bone scanning, 764
-failure, **Tc-pyrophosphate bone uptake, 711
function evaluation, book review, 945
GFR, comparison of inulin, **I-thalamate, **Tc-DTPA, in dogs, 317
GFR, dynamic scan, **Tc-DTPA, deconvolution analysis, 352, 1020
hemangioma, 362
**HgCl uptake, book review, 855
hypertension, 378, 563*, 947
imaging, compared to Saralasin infusion test and renin radioimmunoadsay, **Ht-Hippuran, **Tc-glucophero
nate, 562
imaging, spleen simulation of renal mass, 1104
imaging, \textsuperscript{99m}Tc-glucophoneate, 786
prostaglandin E\textsubscript{2} radioimmunoassay, 860*
renin radioimmunoassay, 562*
Saralasin infusion test, 562*
salivary gland scanning, combined with arterial scan, renovascular hypertension, 378
scanning, \textsuperscript{123}I-Citrate, 872; amyloidosis, 899
studies, book review, 856
\textsuperscript{99m}Tc-DMSA, structure, 565*
\textsuperscript{99m}Tc-EDDA analogs, preparation, distribution, in animals, 565*
\textsuperscript{99m}Tc-MIDA, preparation, distribution, in animals, 633
\textsuperscript{99m}Tc-polyphosphate uptake, 426, 427, 428, 429
\textsuperscript{99m}Tc-S colloid uptake parameters, in rats, 681
ultrasonography, 432*, 766*, 948*, 1124*

**Kidney, blood flow**
audiovisual program review, 669
effect on \textsuperscript{131}I-Hippuran and \textsuperscript{99m}Tc-DTPA curves, 537*
isoleted dog kidney, \textsuperscript{99m}Tc, 1121*
relative, \textsuperscript{131}I-Hippuran, \textsuperscript{99m}Tc-Microspheres, in dogs, 538*
relative, \textsuperscript{113}In-Microspheres, in dogs, 876
to aortic bloodflow index, 537*
80-lens oscilloscope camera, \textsuperscript{99m}Tc-DMSA, 290

**Kidney, renogram**
bloodflow effects, \textsuperscript{131}I-Hippuran, \textsuperscript{99m}Tc-DTPA, 537*
compared to urography, hydronephrosis, 946*
compartamental model, 1121*
in hypertension, 947*
isoleted dog kidney, \textsuperscript{131}I-Hippuran, 1121*
modular programming system, 544*
screening test, usefulness, 439
transplants, \textsuperscript{99m}Tc-DTPA, \textsuperscript{131}I-Hippuran, 537*

**Kidney, transplant**
evaluation, \textsuperscript{131}I-, \textsuperscript{131}I-fibrinogen, \textsuperscript{99m}Tc-S colloid, \textsuperscript{67}Ga-citrate, 175
evaluation, \textsuperscript{99m}Tc-S colloid, 175, 181, 939, 940
kidney to aortic bloodflow index, 537*
lumphocye, ultrasonography, 1028*
renograms, \textsuperscript{131}I-Hippuran, \textsuperscript{99m}Tc-DTPA, 537*
\textsuperscript{99m}Tc-DTPA imaging, body-background defects, 696
ultrasonography, 432*

**Kit**
gastrin radioimmunoassay, 434*
\textsuperscript{131}I-Iodoantipyrine, 1093
\textsuperscript{125}I-digoxin radioimmunoassay, comparisons, 847
\textsuperscript{99m}Tc-HSA, evaluation, 47
\textsuperscript{99m}Tc-pyrophosphate, evaluation, 325*
\textsuperscript{99m}Tc-RBC, 126, 1027*
T\textsubscript{a}, normal range, 665, 666
T\textsubscript{s} radioimmunoassay, 321, 943
unbound \textsuperscript{99m}Tc, 805
vitamin B\textsubscript{12}, absorption, \textsuperscript{64}Co- and \textsuperscript{64}Co-B\textsubscript{12}, 72*

**Krypton-77**
brain blood flow, data analysis, 543*
brain blood flow tomography, 546*

**Krypton-81m**
myocardial imaging, continuous infusion, 535*
nuclear parameters, 401
regional lung ventilation, 530*

**Krypton-85**
package wipe testing, 1013

**Laminar flow**
228

**Lead-203**
acetate, absciss uptake, in rats, 800
leukocyte labeling, 480, 488
RBC labeling, 488

**Legs** see **Extremities**

**Leprosy**
bone imaging, \textsuperscript{99m}Tc-pyrophosphate, 788

**Leukocytes**
\textsuperscript{51}Cr\textsubscript{-}, distribution, in rats, 313
\textsuperscript{99}Ga\textsubscript{-}, absciss imaging, 434*
\textsuperscript{99}Ga labeling, effect of Fe, 852

\textsuperscript{111}In\textsubscript{-}, preparation, distribution, absciss uptake, in dogs, 560*
labeling, 480, 488
surface functional group effects in phagocytosis, 561*
\textsuperscript{Tc} labeling, 730
\textsuperscript{Tc}-, preparation, distribution, bone uptake, in rats, 313
\textsuperscript{Tc-microsphere labeling, distribution, 561*
\textsuperscript{Tc}-monocytes, preparation, chemotactic studies, 988

**Liceenure**
central radiopharmacies, 577

**Limulus amoebocyte lysate**
test sensitivity, 1088

**Lipids**
\textsuperscript{14}C-acetate incorporation, isolated rat epididymis cells, 859*
hyper- and normolipidemic humans, \textsuperscript{111}Se-selenomethionine turnover, 71*
liposome and vesicle labeling, 1102
liposome/trapped \textsuperscript{99m}Tc-DTPA, preparation, distribution, in animals, 1067
vesicles, binding of thyroid antibodies and hormones, 1073
vesicles, interaction with proteins and mammalian cells, 567*

**Liquid scintillation counter**
capsule radioassay, \textsuperscript{61}Co, \textsuperscript{64}I, \textsuperscript{113}I, 434*
quenching curves, 1017

**Liver**
colloid clearance rate, cirrhosis, hepatitis differentiation, 449
comparison of \textsuperscript{99m}Tc-S colloid imaging, ultrasound and axial tomography, 544*
\textsuperscript{65}Cu-agents, 559*
disease, alpha-fetoprotein radioimmunoassay, 159*
disease, carbohydrate metabolism, \textsuperscript{13}CO\textsubscript{2} spirometry, in children, 218
function, alcoholism, 433*
hepatoma, uptake of \textsuperscript{131}I-tetracycline, \textsuperscript{67}Ga-citrate, \textsuperscript{99m}Tc compounds, in rats, 274
\textsuperscript{131}I-indotricarbocyanines, preparation, distribution, in mice, 524*
\textsuperscript{131}I-microaggregated albumin, ultrasonic preparation, distribution, in animals, 72*
\textsuperscript{111}In-bleomycin uptake, effect of dimercaprol, in mice, 1083
liposome/trapped \textsuperscript{99m}Tc-DTPA distribution, in animals, 1067
\textsuperscript{99m}Pb-acetate distribution, in rats, 800
regenerating, \textsuperscript{67}Ga-citrate uptake, in rats, 226
\textsuperscript{99m}Tc-HIDA, preparation, distribution, in animals, 537*, 633
\textsuperscript{99m}Tc-HIDA transport and ultrasonography, in jaundice, 545*
\textsuperscript{99m}Tc-phytate, preparation, distribution, in animals, 389
tomography, axial, 544*
tomography, \textsuperscript{13}NH\textsubscript{3}, 493
tumor, carcinogen induced, effects of radiation, in rats, 715
tumor uptake of \textsuperscript{99m}Tc-diphosphonate, 1060
ultrasonography, 327*, 516*, 544*, 545*
Wilson's disease, \textsuperscript{65}Cu kinetics, 235*

**Liver, blood flow**
adenoama and focal nodular hyperplasia, \textsuperscript{99m}Tc-S colloid, 560*
focal lesions, first pass perfusion, \textsuperscript{99m}Tc-S colloid, 532*
hemangiomna, \textsuperscript{99m}Tc-S colloid, 362

1150

**JOURNAL OF NUCLEAR MEDICINE**
Liver imaging

actinomycosis, "Ga-citrate, \(^{99m}\text{Tc}\)-colloid, 947*
adenoma, focal nodular hyperplasia, \(^{99m}\text{Tc}\)-colloid, 560*
Budd-Chiari syndrome, \(^{186}\text{Au}, \text{U}^{99m}\text{Tc}\)-colloid, 365, 1019
causes of abnormalities, 229
congenital diaphragmatic hernia, \(^{99m}\text{Tc}\)-colloid, 110
hemangioma, "Ga-citrate, \(^{99m}\text{Tc}\)-colloid, ultrasound, 362
image enhancement, fast Fourier transform techniques, 647
malaria, \(^{99m}\text{Tc}\)-colloid, 794
metastases from colon and breast cancer, \(^{99m}\text{Tc}\)-colloid, 677
RES clearance rate of \(^{99m}\text{Tc}\)-colloid, \(^{186}\text{Au}, 449
staging lung cancer, 529*, 530*
superior vena cava obstruction, \(^{99m}\text{Tc}\)-colloid, \(^{99m}\text{Tc}\)-O,
531*
tumor, post Thorotrast, \(^{99m}\text{Tc}\)-colloid, 200
value, 439

Liver scanning

ascitic fluid effects, 1019
Budd-Chiari syndrome, \(^{186}\text{Au}, \text{U}^{99m}\text{Tc}\)-colloid, 365, 1019
to imaging, 419, 421
cystic fibrosis, \(^{99m}\text{Tc}\)-in-colloid, 514*
dextrogastria, \(^{99m}\text{Tc}\)-colloid, 1109
false positive, hepatic amyloidosis, \(^{186}\text{Au}, 31
131I-iodomethylnorcholestenol, \(^{99m}\text{Tc}\)-colloid, metastases
from adrenal carcinoma, 904
jaundice evaluation, 159*
radiotransportation of the great arteries, \(^{131}\text{Xe}, \text{in children, 554*}
-perfusion, \(^{99m}\text{Tc}\)-microspheres, 530*
-perfusion, lymphangitic carcinomatosis, \(^{186}\text{Xe}, \text{MMA, 258
-perfusion, modular programming system, 544*
-perfusion, "N, hyperinflation and Fallot's tetralogy, 233*
-perspiration, pulmonary artery sarcoma, \(^{99m}\text{Tc}\)-HSA, \(^{186}\text{Xe}, 893
-perfusion, pulmonary embolism, 163, 939; \(^{131}\text{Xe}, 613
-perfusion, regional, \(^{131}\text{Xe}, instrumentation, 337
-perfusion, \(^{99m}\text{Tc}\)-phytate aerosol, \(^{99m}\text{Tc}\)-MMA, 707
\(^{99m}\text{Tc}\)-Fe aerosol, 122
\(^{99m}\text{Xe}, effects of decongestant drugs, 541*

Lung

adenocarcinoma, \(^{99m}\text{Tc}\)-O., uptake, 116
bronchogenic carcinoma, chronic bronchitis, CEA levels, 672*
bronchopulmonary sequestration, \(^{99m}\text{Tc}\)-angiography, 1035
cancer, bone imaging, 406
cancer, metastatic to bone, 764*
cancer staging, multiorgan studies, 529*, 530*
131I-iodonium, preparation, distribution, in rabbits, 752
\(^{131}11-	ext{agents, 559*}
\(^{99m}\text{Tc}\)-albumin microspheres, preparation, distribution, in
dogs, 57
\(^{99m}\text{Tc}\)-radiopharmaceutical preparations, 227
hypoxia, effect on cardiac output, in dogs, 542*
liposome trapped \(^{99m}\text{Tc}\)-DTPA distribution, in animals, 1067
pulmonary embolism, 88, 163, 613, 759, 760, 969
retention of \(^{131}1\text{Xe}, 542*
\(^{99m}\text{Tc}\)-microaggregated albumin uptake after MAA
immunization, in rats, 543*
\(^{99m}\text{Tc}\)-colloid uptake, malaria, 794
\(^{99m}\text{Tc}\)-colloid uptake mechanism, in animals, 543*, 681
unilateral hypovascularity, effect on bone images, 27, 853
vascular permeability, \(^{113}1\text{In-transferrin}, in sheep, 541*

Lung imaging

calcification, \(^{99m}\text{Tc}\)-diphosphonate, 858*
causes of abnormalities, 229
inhalation injury, \(^{131}1\text{Xe} in solution, 1120*
interpretation, 531*
perfusion, audiovisual review, 669
perfusion, \(^{99m}\text{Tc}\), 541*
perfusion, unusual anatomy, 623
small ischemic lesions, \(^{14}CO, C^{18}O, inhalation, in dogs, 531*, 866
value as screening test, 439
80-lens oscilloscope camera, 290

Lung ventilation

half-time data processing, \(^{133}1\text{Xe}, 88, 759, 760
\(^{85}Kr, 530*
-perfusion, in D-transportation of the great arteries, \(^{133}1\text{Xe}, \text{in children, 554*}
-perfusion, \(^{85}Kr, \text{\(^{99m}\text{Tc}\)-microspheres, 530*
-perfusion, lymphangitic carcinomatosis, \(^{186}\text{Xe}, \text{MMA, 258
-perfusion, modular programming system, 544*
-perfusion, "N, hyperinflation and Fallot's tetralogy, 233*
-perspiration, pulmonary artery sarcoma, \(^{99m}\text{Tc}\)-HSA, \(^{186}\text{Xe}, 893
-perfusion, pulmonary embolism, 163, 939; \(^{131}\text{Xe}, 613
-perfusion, regional, \(^{131}\text{Xe}, instrumentation, 337
-perfusion, \(^{99m}\text{Tc}\)-phytate aerosol, \(^{99m}\text{Tc}\)-MMA, 707
\(^{99m}\text{Tc}\)-Fe aerosol, 122
\(^{99m}\text{Xe}, effects of decongestant drugs, 541*

Macroaggregated albumin see Technetium-99m, albumin

Mediastinum

malignant fibrous histiocytoma, "Ga-citrate scan, 630

Mercury-197

-chloride, kidney uptake, book review, 855
-chloromerodrin, brain tumor imaging, 417, 418
-chloromerodrin, kidney and adrenal scanning in renovascular
hypertension, 378
-fibrinogen, preparation, 542*
-package wipe testing, 1013
-scan, 943, 944

Merycury-203

-chloromerodrin, kidney extraction efficiency, with \(^{131}1\text{HSA, in dogs, 538*}
-chloromerodrin, -nitate, -BMHP, -fluorescein analogs,
damaged myocardium uptake, in animals, 911

Microaggregated albumin see Iodine-131; Technetium-99m, albumin

Microspheres see Cerium-141; Gallium-68; Niobium-95;
Strontium-85; Technetium-99m

MIRD

radiation dose estimates from \(^{99m}\text{Tc}\), 74

Model

animal, see also specific organ
-compartamental, renogram, 1119 *
dog, carotid-basilar bypass, 948*
-mathematical, bone uptake of \(^{153}1\text{Fe} and \(^{45}Ca, 549*
-mathematical, cerebral blood flow, \(^{131}1\text{Xe}, 159*, 596
-mathematical, RES clearance rates, 449
-rat, acute myocardial infarction, 203

Modulation transfer function

image-intensifier tube scintillation camera, 1008
pinhole collimator, scintillation camera, myocardial
agents, 401
-pocket calculator program, 544*
scintillation camera, \(^{99m}\text{Tc}, digital low-pass filtering, 844
-scan, \(^{99m}\text{Tc}, 142

Volume 17, Number 12 1151
Parathyroid
hyper-, bone involvement evaluation, 533*, 711, 764*
hyperc. myocardial uptake of ⁹⁹mTc-diphosphonate, 896
parathormone radioimmunoassay, book review, 1118

Pediatrics
see also Fetus
bone image in hemoglobinopathy and purpura fulminans,
⁹⁹mTc-pyrophosphate, 1062
brain blood flow, ⁹⁹mTcO₂, 780
brain scanning in perinatal asphyxia, ⁹⁹mTcO₂, 554*
brain tomography, 433*, 948*
bronchopulmonary sequestration, ⁹⁹mTcO₂, angiography, 1035
carbohydrate metabolism in liver disease, spirometry, ¹³C, 218
congenital diaphragmatic hernia, ⁹⁹mTc-S colloid liver image, 110
cystic fibrosis, liver-spleen imaging, ¹³¹I-In-colloid, 514*
⁹⁹mTc-gallium in mother's milk, 223, 1055*
⁹⁹mTc-citrine scanning, solid tumors, 1026*
heart blood flow, in patent duc tus arteriosus, ⁹⁹mTcO₂, 554*
heart, left-to-right shunt detection, ¹³C₀₂, 555*
¹⁸⁷Ga, angiocardiograms, in monkeys, 555*
joint imaging, ⁹⁹mTc-citrate, 554*
joint imaging, ⁹⁹mTc-diphosphonate, 554*
lung ventilation, perfusion, D-transportation of the great arteries, ⁹⁹mTc, 554*
Meckel's diverticulum, ⁹⁹mTcO₂ imaging, 465, 553*
osteoblastoma of the axial skeleton, ⁹⁹mTc-polyphosphate scan, 187
osteomyelitis, bone scanning, 71*, 617, 620, 857*
Pediatric Nuclear Medicine, book review, 512
deltimg, usefulness, 439
pulmonary hyperinflation and Fallot's tetralogy, ventilation, perfusion, ¹⁸⁷Ga, 233*
right and left cardiac output, unusual anatomy, 623
salivary gland uptake of ⁹⁹mTc-citrate after radiotherapy, 685
scrotal imaging for testicular torsion, ⁹⁹mTcO₂, -HSA, 553*
⁹⁹mTc in breast milk, 1024*
⁹⁹mTc-pyridoxylidene glutamate, gallbladder studies, 555*
ultrasonography, craniopharyngioma, 327*
ultrasonography, kidney, 432*
ultrasonography, mass diagnosis, 766*
ultrasonography, mesenteric cyst, 860*

Phosphorus-32
assay, dose calibrator, 404, 1109, 1110
-cromatic phosphate therapy, intracavitary, 150, 151
diphosphonate, bone and bone tumor turnover, in dogs, 548*
diphosphonate, distribution compared to ⁹⁹mTc-diphosphonate, in osteogenic sarcoma, 548*
diphosphonate, -pyrophosphate, -orthophosphate, distribution, in rats, 548*
diphosphonate, therapy, metastatic bone tumor, 548*
package wipe testing, 1013
-phosphate, Limulus test, 1088
-pyrophosphate, distribution, autoradiography, in rats, 1025*
-pyrophosphate, myocardial infarct uptake mechanism, 639

Phosphorus-33
-diphosphonate, distribution, in rats, 548*

Photom absorption
bone Ca in hyperparathyroidism, 533*

Pituitary gland
radiotherapy assay for follicle-stimulating hormone, 326*

hookworm, erythropoietin radioimmunoassay, 1123*
visceral larva migrans, radioimmunoassay, 236*

Molybdenum-99
 package wipe testing, 1013
⁹⁹mTc generator, Pu content, 158*

Muscle
damaged, ⁹⁹mTc-tetracycline uptake, in rats, 432*
skeletal, damaged, ⁹⁹mTc-diphosphonate uptake, in rats, 765*
skeletal, ¹⁸¹Ti, K uptake, effect of cardiac drugs, 535*

Myocardium
Neutrium
⁹⁹mTc generator eluate, 840

Neutron activation analysis
Na turnover in hand, 724
total body Ca, ¹⁸¹Ar excretion, 529*
total body Ca, in osteoporosis, 526*

Nobium-95
-microspheres, relative renal blood flow, in dogs, 876

Nitrogen-13
-alanine, pancreas scanning, 560*
ammonia, brain imaging, 473, 551*
ammonia, brain tomography, 552*, 603
ammonia, heart imaging, collimation, 401
ammonia, heart tomography, 493, 547*, 552, 603
-BNCU, preparation, distribution, in rats, 558*
lung ventilation, perfusion, in neonate, 233*
uclear parameters, 401, 583

Nomenclature see Terminology

Nuclear Medicine Pioneer Citation
David E. Kuhl, M.D., 518

Nuclear parameters see specific radionuclide

Nuclear stethoscope
left ventricular function, ⁹⁹mTc-HSA, 557*

Observer interpretation
lung perfusion and ventilation images, 531* 
myocardial image, acute infarct, ⁹⁹mTc-pyrophosphate, 523*
myocardial image, rest and stress, ¹⁸¹Ti, 522*
myocardial infarct quantitation, ¹³¹I, in dogs, 247

nuclear medicine procedures, 229
value of diagnostic and screening tests, 439

Oscilloscope
camera, 80 lens, 290

Osmium-191
⁹⁹mTc generator, 555*

Ovaries
Book review, Synopsis of Gynecologic Oncology, 669
carcinoma, ⁹⁹mTc-pyrophosphate uptake, 29
radiation dose, ¹⁸¹I thyroid therapy, 539*, 826
radiation dose estimates, ⁹⁹mTcO₂, MIRD, 74

Oxygen-15
¹⁷⁷Ο₂, lung ventilation in ischemia, in dogs, 531*
¹⁷⁷Ο₂ preparation, 866
¹⁷⁷Ο₂ inhalation, left heart imaging, 965
¹⁷⁷Ο₂ inhalation, left-to-right shunt detection, in children, 555*
¹⁷⁷Ο₂, transverse-section brain imaging, 551*
¹⁷⁷Ο₂, preparation, oxidative phosphorylation, in vitro, 558*
nuclear parameters, 866, 965
¹⁷⁷Ο₂, brain imaging, 473
¹⁷⁷Ο₂, inhalation, brain extraction, 1026*

Pancreas
⁵¹C₁⁷-amino acids, preparation, distribution, 557*
disease, Schilling test, 229
imaging, causes of abnormalities, 229
imaging, retrograde, in dogs, 560*
pseudocyst, spleen displacement, 193
scanning, ¹³¹N-alanine, 560*
tomography, 158*
ultrasonography, 432*, 949*, 1124*
ultrasonography, normal, 860*

Parasite
-filarial, ⁹⁹mTc-diphosphonate bone scan, 425
Placenta
blood flow and growth retardation, \(^{99m}\text{Tc}-\text{HSA}, 72^*\)

Platelets see Chromium-51; Indium-111

Plutonium
content, \(^{99m}\text{Tc} \text{ generators, 158}^*\)

Positron
camera, see Camera, positron
emitters, effect of attenuation on reconstruction and noise in tomography, 552^*
imaging, see Carbon-11; Cesium-130; Gallium-68; Krypton-77; Nitrogen-13; Oxygen-15; Rubidium-82
tomograph, 493

Potassium-42
myocardial infarct uptake, effect of cardiac drugs, in dogs, 535^*

package wipe testing, 1013

Potassium-43
coincidence and noncoincidence counting, 153, 154
leukocyte labeling, 480
myocardial imaging, collimation, 401, 719
myocardial imaging, compared to \(^{99m}\text{Tc}, \text{Cs, Rb, in dogs, 880}
myocardial infarct studies, in dogs, 1077

nuclear parameters, 401, 583, 880

package wipe testing, 1013

Probe
--computer system, left ventricular function, 557^*
dual, mobile, left ventricular function, \(^{99m}\text{Tc}-\text{HSA, 930}

joint uptake of \(^{99m}\text{Tc}-\text{diphosphonate, 526}^*\)

Prostate
cancer, metastatic to bone, 253, 548^*, 764^*

\(^{13}C\)-methyl-diaminobutane, preparation, distribution, in rats, 525^*

Proteins
\(^{125}I\), immunology studies of spleen, in rabbits, 1025^*

Pyrophosphate see Phosphorus-32; Technetium-99m, pyrophosphate

Quality control
see also Chromatography

Auger and conversion electron measurement, 72^*
gastrin radioimmunoassay reproductibility, 434^*

Radioimmunoinhibitory effects, 740
Limulus test sensitivity, 1088

Luminescence test, 155

\(^{31}P\) ass analysis, dose calibrator, 404, 1109, 1110

radioimmunoassay of capsules, 434^*

radiochemical purity, 865

scintillation camera, field flow uniformity correction, 653

scintillation camera performance, 665

\(^{99m}\text{Tc} \text{diphosphonate stabilization, 820}

testing, \(^{99m}\text{Tc-fibrinogen, 151, 153}

testing, \(^{99m}\text{Tc-HSA, 704, 758, 759}

testing, \(^{99m}\text{Tc-leukocytes, 730}

testing, \(^{99m}\text{Tc-phytate, 389}

testing, \(^{99m}\text{Tc-RBC, 126, 123}

Radiation damage
effect on carcinogenesis, x-ray, \(^{111m}\text{In, 199Au, in rats, 715}

effect on \(^{60}\text{Ga-citrate serum binding, in rats, 538}

fertility of \(^{131}I\) therapy patients, 460, 532^*

\(^{131}I\) to fetus, 146, 515^*

liver tumor, post Thoriclast, 200

radiotherapy, liver scan defects, 424, 425

Radiation dosimetry
\(^{131}I\) Am sources, fluorescent thyroid scanning, 408

\(^{51}C^*\), \(^{51}C^*\) inhalation, 866

fetus, estimates, \(^{99m}\text{Tc}, \(^{111m}\text{In, 199I, 131I, 125Xe, 539}^*, 836

fetus, \(^{131}I, 146, 515^*\)

infant, \(^{60}\text{Ga-citrate in breast milk, 1055^*}

\(^{131}I\)-hexadecanoic acid for heart imaging, 1077

\(^{125}I\), radiocontaminant effects, 740

\(^{131}I\) in thyroid of grazing animals during nuclear tests, 513^*

\(^{131}I\)-iodomethylnorcholesterol, 540^*

\(^{131}I\), therapy, gonadal dose, 539^*, 826

\(^{131}I\)-phenolphtalein, in animals, 562^*

\(^{153}O\), \(^{153}N\)-ammonia, \(^{185}Ga\)-adenosine triphosphate, 473

perchlorate effect on \(^{99m}\text{Tc-O}, \text{distribution, 540}^*

quantitative uptake methodology, \(^{99m}\text{Tc, 536}^*

\(^{125}S\) tumor therapy, 285

\(^{185}Se\)-selenocholesterol, 212

\(^{99m}\text{Tc}, \text{MIRD, 74}

\(^{99m}\text{Tc}-\text{RBC, 133}

Thorotrust, 200

tissue isotope distribution, 1110

whole-body retention of \(^{125}Xe, 542^*\)

Radiation safety
book review, 512, 1023

procedures for receiving packages, 1013

Radiation therapy
book review, 762
effect on DNA radioimmunoassay, in cancer, 550^*
effect on salivary gland uptake of \(^{60}\text{Ga-citrate, 685}
effects, \(^{99m}\text{Tc-pyrophosphate bone imaging, 527}^*

gynecologic, book review, 669

liver scan defects, 424, 425

Radioassay
plasma glucocorticoid activity of steroids, 158^*

radioresponder, follicle-stimulating hormone, 326^*

radioresponder, insulin, \(^{125}I, 859^*\)

Radiography see Autoradiography

Radioimmunoassay
see also Radiometric Assay; \(^{125}I\); Thyroxine
alpha-fetoprotein, 159^*

angiotensin-I in hypertension, 563^*

antihistamines, 539^*

bleomycin, 550^*, 1123^*

book review, 855

calcitonin, thyroid disease, 533^*

CEA, bronchiogenic carcinoma, chronic bronchitis, 672^*

CEA, effect of age and smoking, 1027^*

CEA, screening test, 236^*

CEA, usefulness, 73^*

cross-reacting cannabinoids in urine, 326^*

curve fitting, 549^*

digoxin, 73^*; kit comparison, 847

DNA, cancer patients, 550^*

erythropoietin, 1123^*

gastrin, reproducibility, 434^*

hepatitis B, 1027^*

inulin, 533^*, 859^*

3-o-methylidopa, 549^*

myoglobin in serum, 765^*

myoglobin, myocardial infarct sizing, in dogs, 534^*

parahormone and calcitonin, book review, 1118

pocket calculator program, 544^*

prolactin, 1027^*

prostaglandin E, 860^*

renin, in hypertension, 562^*

vesicular larva migrans, 235^*

Radiometric assay
bacteria, \(^{14}C\)-glucose, 550^*

digoxin, screening test, 439

Herpes simplex virus in cell culture, \(^{14}C\)-glucose, 503, 550^*

vitamin B, \(^{14}C\)-arginine, 538^*

Radiotherapy
central, FDA regulations, 577

Radium-226
package wipe testing, 1013

Record keeping
system, radiopharmaceutical accountability, 1015

Red blood cells
see also Chromium-51; Technetium-99m, red blood cells

Subject Index
in vivo $^{99mTc}$ labeling, 380, 566*, 941
$^{99mTc}$, $^{111In}$, leukocyte labeling, 488

Resolution
see also Full width at half maximum; Line spread function; Modulation transfer function
germanium semiconductor array, 528*
large-field-of-view scintillation camera, 546*
positron camera, 757
scintillation camera, $^{99mTc}$, 142

Rhodium-101m
preparation, nuclear parameters, 536*

Rose bengal see Iodine-131, rose bengal

Rubidium-81
coincidence and noncoincidence counting, 153, 154
- $^{81mKr}$ generator, 535*
- $^{81mKr}$ generator, lung ventilation, 530*
myocardial imaging, collimation, 401
myocardial imaging, compared to $^{99mTc}$, $^{133Cs}$, $^{99mTc}$, in dogs, 880
myocardial tomography, 547*
nuclear parameters, 401, 880
package wipe testing, 1013

Rubidium-82
positron camera resolution, 757
$^{82Sr}$-$^{82mRb}$ generator evaluation, 536*

Rubidium-82m
nuclear parameters, 401
$^{82mRb}$ contaminant, 880

Rubidium-86
-chloride, tumor blood flow, in animals, 567*
distribution, compared to $^{99mTc}$, in rats, 1120*
package wipe testing, 1013

Ruthenium-103
contaminant, $^{99mTc}$ generator eluate, 840

Salivary glands
$^{67Ga}$-citrate uptake after radiation therapy, 685
imaging, $^{99mTc}$, 961
parotid, $^{67Ga}$ uptake in Sjogren's syndrome, 530*
parotid, ultrasonography, 673*

Scanner
germanium semiconductor array, 528*
scanner, rectilinear
see also specific organ
collimators, heart studies, 583
direct recording on 4 x 5-in. film, 937
dual probe, compared to large field scintillation camera,
$^{67Ga}$-citrate, 547*
dual probe, compared to tomographic, $^{111In}$-bleomycin, 547*

Scanner, tomographic
flying spot x-ray microbeam, 551*
pancreas scanning, $^{32P}$-alanine, 560*

Scatter
Compton, pocket calculator program, 544*

Schilling test see Vitamin B12

Screening
CEA radioimmunoassay, 236*
tests, value, 439

Selenium-75
package wipe testing, 1013
retention, in animals, 236*
-selenocholesterol, adrenal uptake, imaging, in animals, 212
-selenomethionine, leukocyte labeling, 480
-selenomethionine, Limulus test, 1088
-selenomethionine, lipoprotein turnover studies, 71*
selenomethionine, transverse section myocardial tomography, 552*
summation peaks, 943, 944

Skull
see also Brain
computerized axial tomography, 1122*, 1123*

Sodium
metabolism, in hand, neutron activation analysis, 724

Sodium-24
package wipe testing, 1013

Splenic
differential diagnosis of splenomegaly, ultrasonography, 1124*
imaging, cystic fibrosis, 514*
imaging, focal defect, $^{99mTc}$-S colloid, 377
imaging, malaria, $^{99mTc}$-S colloid, 794
imaging, residual function post Thorotrast, $^{99mTc}$-S colloid, 200
immunology, $^{125I}$-protein antibodies, in rabbits, 1025*
liposome trapped $^{99mTc}$-DTPA, distribution, in animals, 1067
RES clearance rate of $^{99mTc}$-S colloid, $^{199Au}$, 449
scan, amyloidosis, $^{99mTc}$-S colloid, 902
scan, displacement by pancreatic pseudocyst, $^{99mTc}$-S colloid, 193
scan, epidermoid cyst, $^{99mTc}$-S colloid, 196
scan, sickle cell anemia, $^{51Cr}$-RBC, $^{111In}$-colloid, 852
sequestration of injection, 944
simulation of renal mass, $^{99mTc}$-glucopohosphate, 1104
$^{99mTc}$-diphosphonate uptake, Hodgkin's disease, 850
$^{99mTc}$-diphosphonate uptake, sickle cell disease, 108
$^{99mTc}$-RBC, preparation, distribution, in animals, 561*, 1038
$^{99mTc}$-RBC uptake, in animals, 942, 943
tomography, $^{125CO}$, 493
ultrasound scatter, 327*

Steroid see also Iodine-131; Selenium-75
plasma glucocorticoid activity, radioreceptor assay, 158*

Stomach see Gastrointestinal tract

Streptokinase see Technetium-99m

Strontium-82
$^{82Rb}$ generator, 536*

Strontium-85
bone scanning, compared to $^{99mTc}$-pyrophosphate kit preparation, 325*
-chloride, distribution, autoradiography, in rats, 1025
-microspheres, relative renal blood flow, in dogs, 538*, 876
myocardial infarct uptake, in rabbits, 534*
package wipe testing, 1013
uptake by surgical wounds, in rats, 566*

Strontium-87m
bone scanning, total hip arthroplasty, 1121*
package wipe testing, 1013
serous fluid excretion, 195

Sulfur-35
distribution, retention, following therapy for tumor, 285
nuclear parameters, 285
package wipe testing, 1013

Surgery
arterial anastomosis, 859*
hip, thrombi, $^{18F}$-fibrinogen uptake, 71*
post-, myocardial infarct detection, 524*
$^{85Sr}$ and $^{99mTc}$-pyrophosphate in wounds, in rats, 566*
thyroid cancer, followup, 532*
uptake of $^{111In}$-platelets, in animals, 561*

Synovium see Joint

Technetium carrier, $^{99mTc}$-HSA preparation, 704
chemical state, in vivo, 421, 422, 423, 424
flow in Sjogren's syndrome, 530*

Technetium-94m
preparation, quantitative uptake methodology, 536*

Technetium-99m
-acetylcysteine, myocardial infarct uptake, in rabbits, 534*
-albumin, see Technetium-99m, albumin
angiograms in D-transportation of the great arteries, in children, 554*
-ascorbic acid, -ascorbic acid-DTPA, brain tumor imaging, 418, 419
-attenuation effect on tomography image, 552*
-chemical state in vivo, 421, 422, 423, 424
-chemical state, radiopharmaceuticals, 562*, 810, 816
-citrate, myocardial infarct uptake, in rabbits, 534*; citrate, unbound **Te, 805
collimation for myocardial imaging, 719
-colloid, first-pass angiograms, 555*
-compounds, staging lung cancer, 530*
-dihydroxybiotinic acid, damaged myocardium uptake, in animals, 911
disodium etidronate, see Technetium-99m, diphosphonate
-DMSA, damaged myocardium uptake, in animals, 911
-DMSA, kidney cell autoradiography, in rats, 536*
-DMSA, kidney perfusion, 80-lens oscilloscope camera, 290
-DMSA, structure, 565*
-DTPA, see Technetium-99m, DTPA
-EDDA analogs, preparation, distribution, in animals, 565*
-EDTMP, preparation, myocardial infarct uptake, in dogs, 508*
-Fe oxide aerosol, preparation, lung ventilation, 122
-fibrinogen, optimal thrombus detection, 563*
-fibrinogen, preparation, 151, 153
-fibrinogen, preparation, distribution, thrombus uptake, in dogs, 40
-glucocerenate, see Technetium-99m, glucocerenate
-HIDA, bile duct patency, 545*
-HIDA, biliary function, 545*, 633
-hydroxyquinoline carboxylate, preparation, distribution, in animals, 907
**Te effect on scintillation camera sensitivity, 1100
-**Te-inorganic phosphate, preparation, distribution, in animals, 857*
-kethoxal-bis(thiosemicarbazone), for gallbladder, preparation, distribution, in animals, 816
-kidney perfusion, isolated, in dogs, 1121*
-leukocyte labeling, 480, 488, 561*, 730
-leukocytes, preparation, distribution, in rats, 313
-mercaptoxybyuric acid, damaged myocardium uptake, in animals, 911
-microspheres, see Technetium-99m, microspheres
-monocytes, labeling, chemotactic studies, 988
-nuclear parameters, 74, 261, 369
-package wipe testing, 1013
-penicillamine complex, preparation, distribution, biliary excretion, in animals, 810
-penicillamine, damaged myocardium uptake, in animals, 911
-phosphate compounds, see also Technetium-99m, diphosphonate: Technetium-99m, polyphosphate; Technetium-99m, pyrophosphate
-phosphate compounds, facial mandibular imaging, 525*
-phosphate compounds, heart imaging, rib erasure, 68
-phosphates, imaging in joint disease, in children, 554*
-phosphonate compounds, distribution, tumor uptake, in rats, 566*
-phytate aerosol, lung ventilation, 707
-phytate, for liver, preparation, distribution, in animals, 536*
-phytate, Limulus test, 1088
-polypeptide, see Technetium-99m, polyphosphate
-pyrophosphate, see Technetium-99m, polyphosphate
-pyrophosphate, quantitative uptake methodology, **Te, 536*
radiation dose to the embryo, 539*, 836
radiochemical purity, 865
-RBC, see Technetium-99m, red blood cells
-S-colloid, see Technetium-99m, sulfur colloid
-Sn-colloid, Limulus test, 1088
-sodium etidronate, see Technetium-99m, diphosphonate
-Solucitran, thyroid imaging, 514*
-streptokinase, preparation, distribution, in animals, 226, 227
-thioglycerol, damaged myocardium uptake, in animals, 911
-transmission scanning, lungs, 541*; unbound, chromatography, 758, 759, 805
Technetium-99m, albumin
cardiac perfusion, 80-lens oscilloscope camera, 290
characterization of preparations, 537*
cisternography, cerebrospinal fluid leak, 797
cisternography, focal uptake, 626
cisternography, spinal descent, 763*
distribution of **Te-chemical phosphate in abdomen, 150, 151
kit evaluation, 47
left ventricular fraction, first-pass, 556*
left ventricular function, 557*, 930
Limulus test, 1088
lung perfusion imaging, 893
-MAA, chemodectoma imaging, 226
-MAA, distribution, myocardial infarct, in rats, 203
-MAA, lung imaging, 541*
-MAA, lung perfusion, 258, 290, 707
-MAA, serial lung scans in embolism, in dogs, 541*
-MAA, thrombus imaging, 564*, 590, 971
-MAA, thrombus scans, 563*
-microaggregated, lung uptake after MAA immunization, in rats, 543*
-placenta imaging, 72*
-preparation, carrier Te effects, 704
testicular torsion imaging, in children, 553*
unbound **Te measurement, 758, 759
Technetium-99m, diphosphonate
ascorbid acid stabilization, 820
bone imaging, see Bone imaging
bone scanning, see Bone scanning
bone uptake dynamics, in animals, 526*
brain imaging, differential diagnosis, with **TeO, 224
calcified myoma uptake, 323
calcium modification, conversion to **Te-glucocerenate, 208
damaged muscle uptake, in rats, 765*
dead cell uptake, tissue culture, 993
distribution compared to **P-diphosphonate, in osteogenic sarcoma, 548*
gluteal tissue uptake after Fe dextran injections, 374
joint imaging, juvenile rheumatoid arthritis, 554*
liver tumor uptake, 1060
lung imaging, calcification, 858*
myocardial infarct imaging, compared to **TeI, in dogs, 534*
myocardial infarct uptake, in rabbits, 534*
myocardial infarct uptake mechanism, in dogs, 534*
myocardial uptake, damaged tissue, in animals, 911
myocardial uptake, renal failure, 896
-net, charge, 562*
-quantitative uptake in rheumatoid arthritis, 525*
soft tissue uptake, filarial infestation, 425
spleen uptake, Hodgkin’s disease, 850
spleen uptake, sickle cell disease, 108
tooth extraction socket uptake, in rats, 688
toxicity of diphosphonate, 417
Technetium-99m, DTPA
brain angiography, arteriovenous shunting, 1057
brain imaging, renal dialysis, 6
brain scan, meningioma, 763*
damaged myocardium uptake, in animals, 911
Technetium-99m, pyrophosphate

- Bone imaging, see Bone imaging
- Bone island uptake, 113
- Bone scanning, see Bone scanning
- Bone uptake and hydroxyproline in bone and urine, 711
- Brain scan, meningioma, 763*
- Dead cell uptake, tissue culture, 993
- Distribution, autoradiography, in rats, 1025*
- Glutal tissue uptake after Fe dextran injections, 374
- Hepatoma uptake, in rats, 274
- In vitro RBC tagging, angiography, 565*
- Kidney uptake, 427
- Kit evaluation, compared to Sr, 325*
- Limulus test, 1088
- Metastatic seminoma uptake, 1105
- Myocardial imaging, arteriosclerosis, myocardiopathy, 241
- Myocardial infarct imaging, 524*
- Myocardial infarct uptake, in rats, 203
- Serous fluid secretion, 195
- Soft tissue tumor uptake, 98
- Soft tissue uptake, kidneys, 426, 427, 428, 429

Technetium-99m, glucophoneate

- Compared to TcO4−, for brain imaging, 345
- Kidney cell autoradiography, in rats, 536*
- Kidney imaging after brain scan, 786
- Kidney imaging, spleen interference, 1104
- Kidney studies in hypertension, 562*
- Myocardial infarct, autoradiography, in rats, 203
- Myocardial infarct uptake, in rabbits, 534*
- Myocardium damage site uptake, in animals, 911
- Net charge, 562*
- Perinephric abscess, subtraction method, with Ga-citrate, 855*

Technetium-99m, microspheres

- Cerebral blood flow, compared to TcO4−, Xe, 170
- Leukocyte labeling, distribution, 488, 561*
- Regional lung perfusion, 88, 530*
- Retrograde pancreas imaging, in dogs, 560*
- Thrombus imaging, 971
- Thorbus scanning, 564*

Technetium-99m, pertechnetate

- Abdominal aortic aneurysm rupture, angiography, 1065
- Angiocardiography in patent ductus arteriosus, 554*
- Bowel loop concentration, in rats, 470
- Brain, blood flow, see Brain, blood flow
- Brain imaging, see Brain imaging
- Brain scanning, see Brain
- Brain tomography, scintillation camera, computer, 551*
- Breast imaging, 223
- Cardiac angiography, see Heart, blood flow
- Cystography, continuous monitoring, 81
- Distribution following Sn(II) complex administration, in rats, 380
- Elute contaminants, 158*, 840
- GI tract imaging, Meckel’s diverticulum, in children, 465, 553*
- Hepatoma uptake, in rats, 274
- In vivo RBC labeling, 566*
- Kaposi sarcoma scanning, 947*
- Limulus test, 1088
- Lung adenocarcinoma uptake, 116
- Lung circulation, dynamic imaging, 541*
- Perchlorate effect on distribution, 528*, 540*
- Radiation dose estimates, MIRD, 74
- Retrograde pancreas imaging, in dogs, 560*
- Salivary gland imaging, 961
- Scrotal imaging for lesions, 71*
- Stomach secretion site, 559*, 756
- Superior vena cava obstruction, 851
- Testicular torsion imaging, in children, 553*
- Thrombosis imaging, 1916
- Thyroid, autonomous functioning nodule uptake rate, 532*
- Thyroid carcinoma, disparate uptake, with I131, 22
- Thyroid imaging, compared to I131, 261, 1023
- Thyroid scan, 983
- Vertebral artery fistula detection, 24

Technetium-99m, polyphosphate

- Bone imaging, see Bone imaging
- Bone scanning, see Bone scanning
- Bone uptake, formazane staining, in rats, 93
- Breast milk concentration, 1024*
- Conversion to Tc-gluconate, 208
- Hepatoma uptake, in rats, 274

myocardial imaging, arteriosclerosis, myocardiopathy, 241
myocardial infarct imaging, 524*
myocardial infarct uptake, in rats, 203
serous fluid secretion, 195
soft tissue tumor uptake, 98
soft tissue uptake, kidneys, 426, 427, 428, 429

Technetium-99m, red blood cells

- Binding, in vivo, 380, 566*
- Hand blood flow in Raynaud's phenomenon, 564*
- Kit preparation, 126, 594, 1027*
- Methods of damaging, spleen uptake, in animals, 561*, 1038
- Preparation, angiography, 565*
- Preparation, stability, 133, 1113, 1114
- Pulmonary vascular perfusion measurements, in sheep, 541*

Technetium-99m, sulfur colloid

- Bolus injection techniques, 564*
- Bone marrow scanning, sickle cell disease, 947*
- Clearance by RES, 449
- Gastroesophageal reflux imaging, therapy effects, 559*
- Jaundice evaluation, 159*
- Kidney transplant evaluation, 175, 181, 939, 940
- Leukocyte labeling, 488
- Liver imaging, see Liver imaging
- Liver perfusion, tumor, 434*
- Liver perfusion, 80-lens oscilloscope camera, 290
- Liver scanning, see Liver scanning
- Lung and kidney uptake, endotoxin, heparin effects, in rats, 681
- Lung deposition mechanism, in animals, 543*
- Lung uptake, malaria, 794
- Regional liver perfusion, focal lesions, 532*
- Retrograde pancreas imaging, in dogs, 560*
- Spleen imaging, see Spleen

Technetium-99m, tetracycline

- Analogs, uptake in myocardial infarct, in rats, 203
- -Oxytetracycline, myocardial uptake, damaged tissue, in animals, 911
- Hepatoma uptake, in rats, 274
myocardial infarct uptake mechanisms, 639
preparation, distribution, damaged muscle uptake, in rats, 432*

Terminology
epidermal, extraluminal hematomata, 986
laminar flow, 228
radiochemical purity, 865
Tc and Tcγ, 759, 760
tissue distribution, 1110

Tests
radiation dose estimates, 1110
Thallium-201
Thallium, myocardial uptake for scintillation imaging, 71*

Terthylene see Iodine-125; Iodine-131; Technetium-99m, terthylene

Thallium-201
collimation for myocardial imaging, 719
distribution, myocardial infarct, in rats, 203
distribution studies, myocardial imaging, 1120*
kidney extraction efficiency, with 131I-HSA, in dogs, 538*
myocardial imaging, background subtraction, 744
myocardial imaging, compared to 125I-Cs, 4K, 4Rb, in dogs, 880
myocardial imaging, reproducibility, 522*
myocardial imaging, rest and stress, 522*; normal, 583
myocardial infarct imaging, 233*, 771
myocardial infarct imaging, compared to 99mTc-diphosphonate, in dogs, 534*
myocardial infarct imaging, dual isotope with 99mTc-pyrophosphate, 524*
myocardial infarct imaging, time of study, 523*
myocardial infarct uptake, effect of cardiac drugs, in dogs, 535*
nuclear parameters, 142, 583, 880
package wipe testing, 1013
quantitative myocardial scanning, 531*
sцинтillation-camera imaging parameters, 142
transient myocardial ischemia imaging, in dogs, 535*
transmission imaging, facial mandibular abnormalities, 525*
transverse-section myocardial tomography, 552*
ventricular contraction patterns, edge delineation, 544*

Therapy
see also Chemotherapy; Radiation therapy
131I for thyroid cancer, fertility of ex-patients, 460, 532*
131I for thyroid cancer, followup, 532*, 672*
131I for thyroid, gonadal radiation dose, 539*, 826
123I thyroid, in pregnancy, 146
131I thyroid, metastatic brain tumor hemorrhage, 307
99mTc-chromic phosphate, distribution, in abdomen, 99mTc-HSA, 150, 151
99mTc-diphosphonate for bone tumor, 548*
S, chordomasoma, chordoma, distribution, retention, 285
Thorotrast, residual splenic function, liver tumor, 200

Thermography
breast carcinoma, 672*
thyroid, cold nodule, 326*

Thrombus
comparison of 99mTc-MAA and contrast venography, 563*
comparison of 99mTc-microspheres and contrast venography, 564*
forming and preformed. 111In-fibrinogen, RISA, in rabbits, 543*
111In-fibrinogen preparation, 542*
123I-fibrinogen, clearance rate, 282
123I-fibrinogen scanning, 325*
111In-fibrinogen uptake, after hip surgery, 71*
111In-fibrinogen uptake in endothelial damage sites, in dogs, 543*

111In-fibrinogen, high specific activity, preparation, imaging, in dogs, 397
imaging, 99mTc-MAA, 590
imaging, 99mTc-MAA, gamma camera and movable bed, 564*
imaging, 99mTc-MAA, microspheres, 969
In-platelet uptake, in animals, 561*
joint uptake of 111In-fibrinogen in venography, 1025*
opimal diagnostic procedures, 563*
pre-formed, 111In-plasminogenen uptake, in dogs, 542*
99mTc-fibrinogen uptake and imaging, in dogs, 40
99mTcO4- venography, 1096
99mTc-S colloid lung uptake mechanism, in animals, 543*
99mTc-streptokinase, preparation, testing, 226, 227

Thyroid
acropachy, 791
99mTc-pyrophosphate bone scan, 791
antithyroglobulin radioimmunooassay, 539*
autonomous functioning nodule, uptake rates of 99mTc-, 532*
blocking, effect of 123I-thyroxine plasma clearance, 657
blocking, 125I-iodomethinonorchestrol adrenal studies, 540*
blocking, perchlorate, 528*, 540*
cancer, disparate uptake of 131I and 99mTcO4-, 22
cancer, followup, effects of treatment, 532*, 672*
cold nodule, ultrasonography, 673*
cold nodule, ultrasonography, thermography, 326*
disease, book review, 1118
disease, effect on calcitonin radioimmunooassay, 533*
fluorescence scanning, 533* Am source, radiation hazard, 408
fluorescence scanning, benign and malignant nodule differentiation, 17
function in gram-negative septicemia, in rats, 104
function tests, 325*
hormone, effect on insulin radioimmunooassay, 533*
131I in grazing animals during nuclear tests, 515*
131I radiation dose to fetus, 515*
123I therapy, fertility of ex-patients, 460, 532*
123I therapy, followup, 532*, 672*
111In therapy, gonadal radiation dose, 539*, 826
111In therapy, in pregnancy, 146
imaging, 99mTcO4-, 111In comparison, 261, 1021
imaging, 99mTc-Solcocitran, 514*
in vitro function tests, in pregnancy, 533*
multinodular, primary and secondary carcinoma with focal nodular hyperplasia, 983
radiation dose estimates, 99mTcO4-, MIRD, 74
scan, 131I, "owl eye" sign in carcinoma, 985
scanning, causes of abnormalities, 229
scanning, 99mTc-citrate, 125I-Cs, 268
scanning, 123I 4 and 24 hr, 1090
uptake, 131I, depth correction, 529*
Tc, normal range, 665, 666
Tc, radioimmunooassay, 321, 411, 943
calcitonin, simultaneous radioimmunooassay, 550*, 660
Tc, effect of fatty acids, 672*
Tc, effects of patient's age, 325*
uptake, 111In liquid, capsule comparison, 310
uptake, 123I, scintillation camera, 359
uptake, value, 439

Thyroid-stimulating hormone
effect of pregnancy on levels, 533*
gram-negative septicemia, in rats, 104
123I, vesicle interactions, 1073
serum, use in thyroid evaluation, 325*
suppression, thyroid nodule uptake rate, 532*
thyroid function, 111In therapy, long-term followup, 672*

Thyreotropin see Thyroid-stimulating hormone

Thyroxine
free, simultaneous T4 measurement, 550*, 660
123I, plasma clearance, effect of blocking dose, 657
index, effect of patient's age, 535*
index, use in thyroid evaluation, 325*
SUBJECT INDEX

in vitro tests, pregnancy effects, 533*
plasma, in gram-negative septicemia, in rats, 104
serum, effect of fatty acids, 672*

Tissue culture
dead cell marking, °°Tc bone agents, 993

Tomography
attenuation effects on reconstruction and statistical noise, 552*
book review, 155, 669
brain, Anger scanner, 547*
brain circulation, °Ga-EDTA, °Kr, 546*
brain, increased intracranial pressure, 157*
brain, scintillation camera, computer, °°TcO2, 551*
brain, senile dementia, 516*
brain tumor, dexamethasone therapy effects, 528*
compared to dual-probe scanning, °°In-bleomycin, 547*
edpidural hematoma, 972
flying spot x-ray microbeam scanner, 551*
head trauma, 1122*
image generation and display, 515*
pancreas, °°N-alanine, 560*
positron, heart, brain, 547*, 552*, 603
positron, brain, 551*
transaxial, brain, in children, 433*
transaxial, scintillation camera, computer, 552*
transverse-section cisternography, °°In-DTPA, 924
transverse-section, myocardium, °°Ca, °°Tl, °°Se-selenomethionine, 552*
transverse, vascular brain lesions, 157*
whole-body positron transaxial tomography, 493
zone plate camera, 526*

Tomography, computerized axial
application to body areas, 158*
brain, compared to brain imaging, 546*, 552*
brain, tumor dexamethasone therapy effect, 528*
cerebral blood volume, data subtraction, 1026*
CSF system, 157*, 765*
liver, compared to imaging and ultrasonography, 544*
information extraction, 157*
normal scan, 516*
pediatric neurology, 948*
skull, 1123*

Tooth
extraction socket, °°Tc-diphosphonate uptake, in rats, 688

Toxicity
diphosphonate, 417
Limulus amoebocyte lysate test, 918, 1088
phenolphthalexin, 562*

Training
American Board of Nuclear Medicine certification, 328

Transferrin see Indium-111

Transmission
see also Tomography, computerized axial
image reconstruction, book review, 155
imaging, °°Tl, facial–mandibular abnormalities, 525*
scanning, lungs, °°Tc, 541*

Trauma
head, cisternography, 119, 233*
head, tomography, 1122*

Tritium see Hydrogen-3

Tuberculosis
see also Lung
meningitis, °°Fb distribution, 545*
peritonitis, 272, 1020

Tumor
adenocarcinoma, °°I-bleomycin uptake, in rats, 385
adrenal, °°I-nor-iodocholesterol, 563*
adrenal, metastatic, °°I-iodomethylmethylionecolesterol liver scan, 904
°°Bi- °°Ibicarbonate, production, radiation dosimetry, 301
bone, °°P- and °°Tc-diphosphonate distribution, 548*
bone, °°P-diphosphonate therapy, 548*
bone, °°P-diphosphonate turnover, in dogs, 548*
book review, Synopsis of Gynecologic Oncology, 669
brain, dexamethasone therapy effect, tomography, 528*
brain, °°Ga-DTPA, multiwire proportional chamber positron camera imaging, 546*

JOURNAL OF NUCLEAR MEDICINE
ovarian carcinoma, \textsuperscript{99m}Tc-pyrophosphate uptake, 29
pancreas, ultrasound, 432*
primary and secondary in thyroid, 983
prostate cancer, metastatic to bone, \textsuperscript{99m}Tc-pyrophosphate
scans, 253
pulmonary artery sarcoma presenting as pulmonary em-
obolism, 893
\textsuperscript{99m}Tc, blood flow, in animals, 567*
\textsuperscript{99m}Rh, preparation, 536*
seminoma, metastatic, \textsuperscript{99m}Tc-pyrophosphate uptake, 1105
\textsuperscript{99m}Tc-phosphonate complexes, distribution, in rats, 566*
thyroid, benign and malignant differentiation, fluores-
cence scanning, 17
thyroid cancer, disparate uptake of \textsuperscript{131}I and \textsuperscript{99m}TcO\textsubscript{4}\textsuperscript{-}, 22
thyroid cancer, "owl eye" sign in \textsuperscript{131}I scan, 985
thyroid, metastatic to brain, post-\textsuperscript{131}I therapy hemorrhage, 307
thyroid, \textsuperscript{99m}Tc-Solarcitran imaging, 514*
thrombolytic and fibrinolytic activity, radioiodo-fibrin,
-fibrinogen, in vitro, 566*
transitional cell carcinoma, \textsuperscript{99m}Tc-pyrophosphate scans, 253
uptake comparison of labeled bleomycin and ionic radio-
label, in animals, 567*
uptake mechanism, radioiodo-fibrinogen, in animals, 567*
T, see Thyroxine
Ultrasound
abdominal abscess, with \textsuperscript{67}Ga-citrate scanning, 545*
abdominal aortic aneurysms, 327*, 763*
abdominal vascular anatomy, 949*
bone, normal and fractured, 672*
book review, 155, 761
brain, through postoperative bone flap, 948*
common bile duct, 860*
craniohypophyngioma, in infant, 327*
differential diagnosis of jaundice, 545*
eye, 327*, 1124*
fetal crown-rump length, 860*
fetal structure defects, 516*, 517*
fetus, hydropic, 1028*
gallbladder cyst, 673*
kidney carbuncle, 1124*
kidney, in infants, 432*
kidney, nonvisualized, 948*
kidney transplants, 432*, 1028*
left ventricular performance, postmyocardial infarct,
671*
legs, after exercise, occlusive arterial disease, 433*
liver, compared to axial tomography and imaging, 544*
liver, disease patterns, 516*
liver, hemangiomma, 362
liver, venous anatomy, 949*
malignant lymphoma, 1028*
mesenteric cyst, 860*
nebulizer, radioaerosol, 707
neck nodes, 517*
pancreas, 432*, 1124*, normal, 860*
parotid gland, 673*
pelvic inflammatory mass, 1028*
percutaneous puncture guidance, 432*
posterior fossa cyst, 766*
spleen, 1124*
thrombus detection, 563*
thyroid nodules, 326*, 673*
tissue scatter, 327*
urinary tract, 766*
Urinary tract
infection, \textsuperscript{51}Ga-citrate imaging, 1025*
vesicoureteral reflux monitoring, \textsuperscript{99m}TcO\textsubscript{4}\textsuperscript{-}, 81
ultrasongraphy, 766*
Uterus
calciﬁed myoma, \textsuperscript{99m}Tc-diphosphonate uptake, 323
Vascular system
see also speciﬁc organ; Thrombus
abdominal aortic aneurysm, angiography, 765*, 1065
abdominal aortic aneurysm, ultrasonography, 327*, 765*
abdominal, ultrasonography, 949*
aviologic program; Radionuclide Angiography, 669
bolus injection technique, 564*
carotid artery, surface uptake of \textsuperscript{131}I-albumin, in vitro, in
dog, 234*
carotid-basilar bypass, in dogs, 948*
carotid endartectomy, 234*
chemodectomy, carotid body, 225
D-transplantation of the great arteries, lung ventilation,
perfusion, \textsuperscript{99m}Tc angiography, \textsuperscript{133}Xe, in children, 554*
"In-EDTA-HSA, preparation, distribution, 561*
internal jugular vein reﬂux, 61, 225
occlusive artery disease, exercise testing, ultrasound, \textsuperscript{133}Xe
clearance, 433*
superior vena cava obstruction, \textsuperscript{99m}Tc-S colloid scan,
\textsuperscript{99m}TcO\textsubscript{4}\textsuperscript{-}angiography, 851
\textsuperscript{99m}TcO\textsubscript{4}\textsuperscript{-}angiocardiography in patent ductus arteriosus,
534*
vertebral artery ﬁstula, \textsuperscript{99m}TcO\textsubscript{4}\textsuperscript{-} studies, 24
Ventriculagram
ventricular size after shunting, 514*
Vesiicles see Lipois
Viruse
radiometric assay, 503, 550*
Vitamin \textsubscript{B}\textsubscript{12}
absorption, celiac disease, small bowel resection, 235*
absorption, dual-isotope kit, 72*
absorption, pocket calculator program, 544*
radioassay, toadsh serum binder, 737
radiometric assay, \textsuperscript{14}C-arginine, 538*
Schilling test, causes of abnormalities, 229
Well scintillation counter
\textsuperscript{17}O assay, 220, 943, 944
Xenon-127
whole-body retention, 542*
Xenon-133
radiation dose estimates to the embryo, 539*, 836
Xenon-133, gas
lung ventilation, effects of decongestant drugs, 541*
lung ventilation, half-time distribution images, 88
lung ventilation imaging, 893
lung ventilation, lymphangitic carcinomatosis, 258
lung ventilation, perfusion, pulmonary embolism, 613
lung ventilation, perfusion, regional, instrumentation,
337
Xenon-133, in solution
bowel clearance, in dogs, 235*
brain blood flow, see Brain, blood flow
inhalation injury diagnosis, 1120*
lung ventilation, perfusion, D-transportation of the great
arteries, in children, 554*
muscle clearance after exercise, occlusive artery disease,
1033*
myocardial clearance, coronary blood flow, in dogs, 1044
package wipe testing, 1013
X-Ray
see also Tomography, computerized axial
bone involvement in hyperparathyroidism, 533*
book review, 155
comparred to lung ventilation and perfusion imaging,
530*
2nd ANNUAL WESTERN REGIONAL MEETING
THE SOCIETY OF NUCLEAR MEDICINE
October 21–23, 1977
Aladdin Hotel
Las Vegas, Nevada

ANNOUNCEMENT AND FIRST CALL FOR ABSTRACTS FOR SCIENTIFIC PROGRAM

The Scientific Program Committee welcomes the submission of abstracts of original contributions in nuclear medicine from members and nonmembers of the Society of Nuclear Medicine for the 2nd Annual Western Regional Meeting. Physicians, Scientists, and Technologists, members and nonmembers are invited to participate. The Program will be structured to permit the presentation of papers from all areas of interest in the specialty of Nuclear Medicine. Abstracts for the scientific program will be printed in the program booklet and will be available to all registrants at the meeting.

GUIDELINES FOR SUBMITTING ABSTRACTS

The abstracts will be printed from camera-ready copy provided by the authors. Therefore, only abstracts prepared on the official abstract form will be considered. Request for the official abstract forms should be made to:

Jean Lynch, Administrative Coordinator
SNM Western Regional Meeting
P.O. Box 40279
San Francisco, CA 94140

Abstract forms will only be sent to SNM members of the Pacific Northwest, Southern California, Northern California, and Hawaii Chapters in a regular mailing. All other requests will be sent on an individual basis.

The original and six copies of the completed abstract and supporting data are to be sent to:

Naomi Alazraki, M.D.
Scientific Program Chairman
2037 Soledad Avenue
La Jolla, CA 92037

Deadline for abstract submission: July 1, 1977

All participants are required to register and pay the appropriate fee.

The 2nd Annual Western Regional Meeting will have commercial exhibits and all interested companies are invited. Please contact Jean Lynch, P.O. Box 40279, San Francisco, CA 94140. Phone: (415) 647-1668.
SYMPOSIUM ON COMPUTER-ASSISTED DATA PROCESSING IN NUCLEAR MEDICINE
January 16–17, 1977
Hyatt Regency Hotel
Atlanta, Georgia

Members and nonmembers of the Society of Nuclear Medicine are invited to attend the annual scientific program of the SNM Computer Council, to be held January 16–17, 1977, at the Hyatt Regency Hotel in Atlanta, Georgia. This meeting will be held immediately following the midwinter meeting of the SNM Board of Trustees and the topical symposium.

The program will include lectures by invited specialists in the field, as well as selected research papers of merit. The Scientific Program Committee welcomes the submission of abstracts for presentation in the areas of cardiovascular, pulmonary, renal, and cerebral vascular computer-assisted imaging and data-processing applications, algorithms, software and hardware development. The proceedings of the meeting will be published and the final manuscripts must be submitted at the time of presentation.

Abstracts are limited to a maximum of 350 words and must be submitted by December 15th, 1976. Abstracts should be submitted to:

David A. Weber, Ph.D.
Program Chairman
Division of Nuclear Medicine
University of Rochester Medical Center
Rochester, New York 14642

The program has been submitted for credit toward the AMA Physicians' Recognition Award under Continuing Medical Education Category 1.

ANNOUNCEMENT

The Education and Research Foundation of the Society of Nuclear Medicine welcomes applications for two of its projects.

■ Medical Student Fellowship Program: This educational project is designed to stimulate interest among medical students in the United States and Canada in the field of nuclear medicine. It will make it possible for interested and qualified students to spend elective quarters and summers in active nuclear medicine laboratories working and associating with experts in the field. Maximum grant: $1,000. Application letters in duplicate, including a description of the project and budget, should be sent to the President of the Foundation, c/o Society of Nuclear Medicine, 475 Park Avenue South, New York, New York 10016.

■ Pilot Research Grants in Nuclear Medicine: The goal of this research support is to provide limited sums of money to scientists to support deserving projects that are pilot in nature. It is hoped that it will make it possible for nuclear medicine scientists to apply for small sums of money for clinical and basic research and to get a decision within a short time following application. The grants will not support salaries, major equipment purchases or travel, but are designed to provide essential materials so that innovative ideas can be quickly tested. Maximum grant $1,000. Application forms are available from the President of the Foundation, c/o Society of Nuclear Medicine, 475 Park Avenue South, New York, New York 10016.
Veterans Administration Hospital
University of Minnesota

NUCLEAR MEDICINE
RESIDENCY PROGRAM

Resident positions are available in an AMA approved two-year training program beginning January 1, 1977. A combined University of Minnesota-VA Hospital program with active clinical and research opportunities. Minimum stipend $15,100.

An Equal Opportunity Employer

For further information, contact:
Rex B. Shafer, M.D., Chief, Nuclear Medicine Service (115), Veterans Administration Hospital, 54th Street & 48th Avenue South, Minneapolis, MN 55417

OR

Merle K. Loken, M.D., Ph.D., Director, Division of Nuclear Medicine, University of Minnesota Hospitals, Box 382, Mayo Memorial Building, Minneapolis, MN 55455

FELLOWSHIP IN COMPUTER SCIENCE—NUCLEAR MEDICINE

The Andre Meyer Department of Physics—Nuclear Medicine (Mt. Sinai Hospital) is sponsoring individuals for a 2 year program in the Application of Computer Sciences to Nuclear Medicine. The program is funded by the National Library of Medicine. The faculty at the Department of Computer Sciences provides an intensive didactic program. Nuclear Medicine serves as a laboratory for the application of the concepts and skills. Candidates should have a background in Nuclear Medicine or another clinical specialty in which a combination of nuclear medicine and computer science techniques will provide a basis for fruitful research. Interested candidates contact:

Stanley J. Goldsmith, M.D., Director
Andre Meyer Department of Physics—Nuclear Medicine
Mount Sinai School of Medicine
Fifth Avenue & 100th Street
New York, N.Y. 10029

STANFORD UNIVERSITY SCHOOL OF MEDICINE

Nuclear Medicine Residency Program—1977/78

Resident positions are available beginning September 1, 1977, for a 2-year program at Stanford University Medical Center and its affiliate Veterans' Administration Hospital. Patients from the Children's Hospital at Stanford are also studied or treated at the University Hospital.

The program goal is to provide well-rounded training to prepare the physician for a career in nuclear medicine. The program, approved by the AMA and satisfying the requirements of the American Board of Nuclear Medicine, includes didactic instruction in radiologic mathematics and physics, radiation safety, dosimetry, electronics, and nuclear medicine instrumentation. A major portion provides practical experience in dynamic and static imaging, computer assisted data manipulation, radioimmunoassay methodology, other in vitro test procedures, and radiopharmacy as part of an integrated patient care program, both diagnostic and therapeutic. Our residents are encouraged to participate in ongoing teaching activities and in one or more research projects under preceptor supervision.

Stanford is an equal opportunity affirmative action employer.

Requests for further information (include C.V. and reference list) should be directed to:

Joseph P. Kriss, M.D.
Director, Division of Nuclear Medicine
Stanford University Medical Center
Stanford, CA 94305
BAYLOR COLLEGE OF MEDICINE, DEPARTMENT OF RADIOLOGY, 
NUCLEAR MEDICINE SECTION 
FELLOWSHIP AND RESIDENCY PROGRAM, 1977–78

Residency and fellowship positions are available in an AMA approved residency program which includes training in two large nuclear medicine laboratories; 1) St. Luke's Episcopal-Texas Children's Hospitals and The Texas Heart Institute joint facilities and 2) Ben Taub General Hospital.

Residency training encompasses the full spectrum of nuclear medicine procedures, both in vivo and in vitro, in pediatric and adult patients. A mobile nuclear medicine capability emphasizes critically ill patients. Because of a substantial commitment to education, including a bachelor's degree program in nuclear medicine technology, the faculty of the Nuclear Medicine Section is very broad based. Trainees attend lectures and laboratories in radiation physics, instrumentation, radiopharmacy, radioimmunoassay, radiobiology, and radiation health in addition to the usual clinical nuclear medicine courses and seminars.

Fellowships (2) with emphasis on cardiac and pulmonary disease are available in association with the Texas Heart Institute. With the mobile capabilities and a large population of critically ill patients (total hospital beds, 1000; intensive care beds, 100), participation in one of the most rapidly growing areas of clinical nuclear medicine is possible with potential for participation in several research projects related to cardiovascular, pulmonary, and critical care nuclear medicine.

Requests for further information should be directed to John A. Burdine, M.D., Chief, Nuclear Medicine Section, or Paul H. Murphy, Ph.D., Residency and Fellowship Coordinator, Department of Radiology, Baylor College of Medicine, Houston, Texas 77030.

NUCLEAR MEDICINE RESIDENCY

Program Directors
Stanley J. Goldsmith, M.D.
Mount Sinai Hospital
Rosalyn S. Yalow, Ph.D.
Bronx Veterans Administration Hospital

A 2 year program in Nuclear Medicine to prepare candidates for examination by the American Board of Nuclear Medicine is available beginning January or July 1977.

The program includes didactic and practical experience in the physics of nuclear medicine, instrumentation, imaging, in-vivo dynamic studies, computer analyses, radioimmunoassay, and radiochemistry. There is emphasis on correlation with clinical data derived from patient examination and radiologic procedures as well as an opportunity for basic or clinical investigation. Candidates are expected to have a 2 year background in internal medicine and/or radiology. Stipend commensurate with background. Send curriculum vitae to Stanley J. Goldsmith, M.D., Director, Andre Meyer Department of Physics—Nuclear Medicine, Mount Sinai School of Medicine, Fifth Avenue & 100th Street, New York, N.Y. 10029.

NUCLEAR MEDICAL TECHNOLOGIST

Nuclear Medicine Technologist (part time and full time) for 600 bed teaching hospital providing excellent experience and opportunity for continued learning. Excellent fringe benefits. Registered in Nuclear Medicine or graduate of A.M.A. approved Nuclear Medicine program. Equal opportunity employer.

Send resume to:
Mr. Joseph Wander
University of Ill. Medical Center
840 S. Wood
Chicago, Ill. 60612
Tel. (312) 996-7293

Methodist Hospital of Gary
600 Grant Street
Gary, Indiana 46402
an equal opportunity employer
### INDEX TO ADVERTISERS

<table>
<thead>
<tr>
<th>Advertiser Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ackerman Nuclear</td>
<td>13A, 62A</td>
</tr>
<tr>
<td>Cernitos, Calif.</td>
<td></td>
</tr>
<tr>
<td>Amersham/Searle</td>
<td>31A</td>
</tr>
<tr>
<td>Arlington Heights, Ill.</td>
<td></td>
</tr>
<tr>
<td>Atomic Development</td>
<td>77A</td>
</tr>
<tr>
<td>Plainview, N.Y.</td>
<td></td>
</tr>
<tr>
<td>Atomic Products</td>
<td>73A</td>
</tr>
<tr>
<td>Center Moriches, N.Y.</td>
<td></td>
</tr>
<tr>
<td>Baird-Atomic</td>
<td>34A, 35A</td>
</tr>
<tr>
<td>Bedford, Mass.</td>
<td></td>
</tr>
<tr>
<td>Brattle Instruments</td>
<td>IBC</td>
</tr>
<tr>
<td>Cambridge, Mass.</td>
<td></td>
</tr>
<tr>
<td>Capintec, Inc.</td>
<td>20A, 21A</td>
</tr>
<tr>
<td>C.I.S. Radiopharmaceuticals</td>
<td></td>
</tr>
<tr>
<td>Bedford, Mass.</td>
<td></td>
</tr>
<tr>
<td>Cleon Corp.</td>
<td>63A</td>
</tr>
<tr>
<td>Needham, Mass.</td>
<td></td>
</tr>
<tr>
<td>Clinical Assays</td>
<td>2A, 53A</td>
</tr>
<tr>
<td>Cambridge, Mass.</td>
<td></td>
</tr>
<tr>
<td>Diagnostic Isotopes</td>
<td>16A, 17A, 69A</td>
</tr>
<tr>
<td>Upper Saddle River, N.J.</td>
<td></td>
</tr>
<tr>
<td>Diagnostic Products</td>
<td>44A</td>
</tr>
<tr>
<td>Los Angeles, Calif.</td>
<td></td>
</tr>
<tr>
<td>Dunn Instruments</td>
<td>55A</td>
</tr>
<tr>
<td>San Francisco, Calif.</td>
<td></td>
</tr>
<tr>
<td>Eastman Kodak Co.</td>
<td>36A, 37A</td>
</tr>
<tr>
<td>Rochester, N.Y.</td>
<td></td>
</tr>
<tr>
<td>Elscint, Inc.</td>
<td>66A, 67A, 75A</td>
</tr>
<tr>
<td>Hackensack, N.J.</td>
<td></td>
</tr>
<tr>
<td>G.E. Medical Systems</td>
<td>14A, 15A</td>
</tr>
<tr>
<td>Milwaukee, Wis.</td>
<td></td>
</tr>
<tr>
<td>Hoechst</td>
<td>5A</td>
</tr>
<tr>
<td>Frankfurt, Germany</td>
<td></td>
</tr>
<tr>
<td>Isolab, Inc.</td>
<td>46A</td>
</tr>
<tr>
<td>Akron, Ohio</td>
<td></td>
</tr>
<tr>
<td>Jasins &amp; Sayles</td>
<td>65A</td>
</tr>
<tr>
<td>Framingham, Mass.</td>
<td></td>
</tr>
<tr>
<td>R. S. Landauer</td>
<td>12A</td>
</tr>
<tr>
<td>Glenwood, Ill.</td>
<td></td>
</tr>
<tr>
<td>Litton Publications</td>
<td>32A</td>
</tr>
<tr>
<td>Oradell, N.J.</td>
<td></td>
</tr>
<tr>
<td>Matrix Instruments</td>
<td>47A, 59A</td>
</tr>
<tr>
<td>Cloister, N.J.</td>
<td></td>
</tr>
<tr>
<td>Medcorp</td>
<td>39A</td>
</tr>
<tr>
<td>Inglewood, Calif.</td>
<td></td>
</tr>
<tr>
<td>Medi-Physics, Inc.</td>
<td>IFC, 1A, 57A</td>
</tr>
<tr>
<td>Emeryville, Calif.</td>
<td></td>
</tr>
<tr>
<td>Medi-Ray, Inc.</td>
<td>3A</td>
</tr>
<tr>
<td>Tuckahoe, N.Y.</td>
<td></td>
</tr>
<tr>
<td>New England Nuclear</td>
<td>8A, 22A, 23A, 72A</td>
</tr>
<tr>
<td>Boston, Mass.</td>
<td></td>
</tr>
<tr>
<td>Nuclear Associates</td>
<td>45A, 68A</td>
</tr>
<tr>
<td>Westbury, N.Y.</td>
<td></td>
</tr>
<tr>
<td>Nuclear-Medical Systems</td>
<td>40A, 52A</td>
</tr>
<tr>
<td>Newport Beach, Calif.</td>
<td></td>
</tr>
<tr>
<td>Ohio Nuclear, Inc.</td>
<td>24A, 25A</td>
</tr>
<tr>
<td>Solon, Ohio</td>
<td></td>
</tr>
<tr>
<td>Omnimedical Services</td>
<td>48A</td>
</tr>
<tr>
<td>Paramount, Calif.</td>
<td></td>
</tr>
<tr>
<td>Picker Corp.</td>
<td>60A, 61A</td>
</tr>
<tr>
<td>Cleveland, Ohio</td>
<td></td>
</tr>
<tr>
<td>Procter &amp; Gamble</td>
<td>18A, 19A, 20A</td>
</tr>
<tr>
<td>Cincinnati, Ohio</td>
<td></td>
</tr>
<tr>
<td>Radiochemical Centre</td>
<td>26A, 38A, 58A</td>
</tr>
<tr>
<td>Amersham, England</td>
<td>64A, 76A</td>
</tr>
<tr>
<td>Newport Beach, Calif.</td>
<td></td>
</tr>
<tr>
<td>Radx Corp.</td>
<td>42A, 43A, 56A</td>
</tr>
<tr>
<td>Houston, Texas</td>
<td></td>
</tr>
<tr>
<td>Ramco Labs.</td>
<td>54A</td>
</tr>
<tr>
<td>Houston, Texas</td>
<td></td>
</tr>
<tr>
<td>Raytheon Corp.</td>
<td>6A</td>
</tr>
<tr>
<td>Burlington, Mass.</td>
<td></td>
</tr>
<tr>
<td>Searle Radiographics</td>
<td>BC</td>
</tr>
<tr>
<td>Des Plaines, Ill.</td>
<td></td>
</tr>
<tr>
<td>SNM Placement</td>
<td>49A, 50A, 51A</td>
</tr>
<tr>
<td>New York, N.Y.</td>
<td></td>
</tr>
<tr>
<td>E. R. Squibb &amp; Sons</td>
<td>41A, 70A, 72A</td>
</tr>
<tr>
<td>Princeton, N.J.</td>
<td></td>
</tr>
<tr>
<td>T.A.C., Inc.</td>
<td>33A</td>
</tr>
<tr>
<td>Lisle, Ill.</td>
<td></td>
</tr>
<tr>
<td>Technical Associates</td>
<td>74A</td>
</tr>
<tr>
<td>Canoga Park, Calif.</td>
<td></td>
</tr>
<tr>
<td>Varian Associates</td>
<td>10A, 11A</td>
</tr>
<tr>
<td>Palo Alto, Calif.</td>
<td></td>
</tr>
</tbody>
</table>

78A